Exhibit 10.54

 

EXECUTION COPY

 

Confidential Materials omitted and filed separately with the
Securities and Exchange Commission. Asterisks denote omissions.

 

 

 

ASSET PURCHASE AGREEMENT

 

by and between:

 

MOMENTA PHARMACEUTICALS, INC.,

a Delaware corporation; and

 

VIRDANTE PHARMACEUTICALS, INC.,
a Delaware corporation.

 

--------------------------------------------------------------------------------

 

Dated as of December 2, 2011

 

--------------------------------------------------------------------------------

 

--------------------------------------------------------------------------------

 

ASSET PURCHASE AGREEMENT

 

THIS ASSET PURCHASE AGREEMENT is entered into as of December 2, 2011, by and
between: MOMENTA PHARMACEUTICALS, INC., a Delaware corporation (the “Purchaser”)
and VIRDANTE PHARMACEUTICALS, INC., a Delaware corporation (the “Seller”). 
Certain capitalized terms used in this Agreement are defined in Exhibit A.

 

RECITALS

 

A.                                    The Seller wishes to sell to the Purchaser
and the Purchaser wishes to purchase from the Seller the Transferred Assets (as
defined in Section 1.1), representing substantially all of the assets of the
Seller, for the consideration, on the terms, and subject to the conditions, set
forth in this Agreement.

 

AGREEMENT

 

The parties to this Agreement, intending to be legally bound, agree as follows:

 

1.                                      SALE OF TRANSFERRED ASSETS; RELATED
TRANSACTIONS.

 

1.1                               Sale of Transferred Assets.  At the Closing
(as defined in Section 1.7), the Seller shall sell, assign, transfer, convey and
deliver to the Purchaser, and the Purchaser shall purchase and acquire from the
Seller, all of the Transferred Assets, free of any Encumbrances, on the terms
and subject to the conditions set forth in this Agreement.  For purposes of this
Agreement, “Transferred Assets” shall mean the following assets and properties
of the Seller existing as of the Closing (but excluding the Excluded Assets (as
defined below)):

 

(a)                                 Intellectual Property and Intellectual
Property Rights: All of the Intellectual Property and Intellectual Property
Rights that are owned or controlled by the Seller and that are or were used in,
necessary for the conduct of, or related to, the Business, including the
Intellectual Property and Intellectual Property Rights identified on Schedule
1.1(a), together with the goodwill associated with the Transferred Assets (the
Intellectual Property, Intellectual Property Rights and goodwill referred to in
this Section 1.1(a) collectively being referred to in this Agreement as the
“Transferred IP”);

 

(b)                                 Tangible Assets: All tangible assets set
forth on Schedule 1.1(b);

 

(c)                                  Contracts:  All rights of the Seller under
the Seller Contracts set forth on Schedule 1.1(c) (the Seller Contracts referred
to in this Section 1.1(c) being referred to as the “Transferred Contracts”);

 

(d)                                 Claims:  All Claims (including Claims for
past infringement of Transferred Assets and Claims for insurance benefits,
rights and proceeds) of the Seller against other Persons relating to the
Transferred Assets (regardless of whether or not such Claims have been asserted
by the Seller), and all rights of indemnity, warranty rights, rights of
contribution, rights to refunds, rights of reimbursement and other rights of
recovery possessed by the Seller (regardless of whether such rights are
currently exercisable) relating to the Transferred Assets; and

 

(e)                                  Records, Etc.:  All of Seller’s records set
forth on Schedule 1.1(e) (such documents referred to in this
Section 1.1(e) being referred to as the “Transferred Records”).

 

1.2                               Excluded Assets.  Notwithstanding anything to
the contrary contained in this Agreement, the parties agree that the Seller is
not selling, assigning, transferring, conveying or delivering to the

 

1

--------------------------------------------------------------------------------

 

Purchaser, and the Transferred Assets shall not include, any of the Excluded
Assets, and such Excluded Assets shall remain the property of the Seller after
the Closing.

 

1.3                               Purchase Price.  As consideration for the
sale, assignment, transfer, conveyance and delivery of the Transferred Assets to
the Purchaser:

 

(a)                                 on the date hereof (the “Closing Date”), the
Purchaser shall pay, or cause to be paid, to the Seller, in cash, a total of
$4,500,000, by wire transfer of immediately available funds to an account number
provided to the Purchaser by the Seller; and

 

(b)                                 subject to any right of setoff that any
Purchaser Indemnitee may be entitled to exercise (pursuant to Section 4.2(d) or
otherwise), the Purchaser shall pay, or cause to be paid, to the Seller the
amounts on the dates set forth below (collectively, the “Milestone Payments”) if
and solely to the extent the Milestones are achieved in accordance with the
terms and conditions of Exhibit F hereto:

 

(i)                                    on the Milestone Payment Date (as defined
on Exhibit F hereto) for Milestone #1A as set forth on Exhibit F hereto, the
Purchaser will pay to the Seller an amount equal to $[**];

 

(ii)                                on the Milestone Payment Date for Milestone
#1B as set forth on Exhibit F hereto, the Purchaser will pay to the Seller an
amount equal to $[**];

 

(iii)                            on the Milestone Payment Date for Milestone #1C
as set forth on Exhibit F hereto, the Purchaser will pay to the Seller an amount
equal to $[**];

 

(iv)                             on the Milestone Payment Date for Milestone #2A
as set forth on Exhibit F hereto, the Purchaser will pay to the Seller an amount
equal to $[**];

 

(v)                                 on the Milestone Payment Date for Milestone
#2B as set forth on Exhibit F hereto, the Purchaser will pay to the Seller an
amount equal to $[**];

 

(vi)                             on the Milestone Payment Date for Milestone #2C
as set forth on Exhibit F hereto, the Purchaser will pay to the Seller an amount
equal to $[**];

 

(vii)                         on the Milestone Payment Date for Milestone #3A as
set forth on Exhibit F hereto, the Purchaser will pay to the Seller an amount
equal to $[**];

 

(viii)                     on the Milestone Payment Date for Milestone #3B as
set forth on Exhibit F hereto, the Purchaser will pay to the Seller an amount
equal to $[**]; and

 

(ix)                             on the Milestone Payment Date for Milestone #3C
as set forth on Exhibit F hereto, the Purchaser will pay to the Seller an amount
equal to $[**].

 

1.4                               Assumption of Certain Liabilities.

 

(a)                                 Subject to Section 1.4(b), the Purchaser
shall not assume any Liabilities of the Seller (whether or not related to the
Transferred Assets or the Business), including without limitation: (i) any
Liabilities of the Seller relating to the Excluded Assets; (ii) any Tax
Liabilities of the Seller, except to the extent allocated to the Purchaser under
Sections 1.5 and 5.4(b); (iii) any Liabilities of the Seller relating to
accounts payable or other indebtedness; (iv) any wages or salaries or other
Liabilities relating to employment (or termination of employment) of any
employees of the Seller (including accrued

 

2

--------------------------------------------------------------------------------

 

vacation); (v) any Liabilities under any Seller Contracts (other than
Liabilities relating to Transferred Contracts that arise after the Closing
Date); or (vi) any other Liabilities of the Seller.

 

(b)                                 Notwithstanding Section 1.4(a) or any other
provision of this Agreement to the contrary, from and after the Closing, the
Purchaser shall assume, discharge and perform as and when due all of the
obligations of the Seller under the Transferred Contracts, including assuming
liability for any claims based on or relating to the transfer of the Product
Materials acquired from [**] by the Seller to the Purchaser pursuant to this
Agreement, but in any case only to the extent that such obligations: (i) arise
after the Closing Date and (ii) do not arise from or relate to any breach by the
Seller of any provision of any of such Transferred Contracts; and (iii) do not
arise from or relate to any event, circumstance or condition occurring or
existing on or prior to the Closing Date that, with notice or lapse of time,
would constitute or result in a breach of any of such Transferred Contracts (the
“Assumed Liabilities”). Notwithstanding the terms of that certain Consent Letter
by and among the Purchaser, the Seller and The Rockefeller University, dated
November 30, 2011 (the “Consent Letter”), for purposes of clarity, the Seller
acknowledges and agrees that the Purchaser is only assuming the obligations of
the Seller under the Rockefeller License Agreement and the Ancillary Agreements
(as defined in the Consent Letter) subject to the limitations set forth in the
prior sentence and, if any conflict exists between the Consent Letter and this
Agreement, this Agreement shall control as between Seller and Purchaser.

 

1.5                               Transaction Taxes.  The Purchaser and the
Seller shall each be liable for one-half (1/2) of any sales Taxes, use Taxes,
transfer Taxes or similar Taxes, charges or fees (“Transaction Taxes”) that may
become payable by the party under applicable Law in connection with the
conveyance and transfer of the Transferred Assets to the Purchaser or in
connection with any of the other Transactions.  The Purchaser and the Seller
shall each use reasonable efforts to avail themselves of any available
exemptions from any such Transaction Taxes and to cooperate with each other in
providing any information and documentation that may be reasonably necessary to
obtain such exemptions.

 

1.6                               Allocation.  The Purchase Price Allocation set
forth on Schedule 1.6 (the “Allocation Schedule”) shall be used by the Seller
and the Purchaser for all purposes, including preparation and filing of Internal
Revenue Service Form 8594, and no party hereto shall take or assert any position
inconsistent therewith.

 

1.7                               Closing.

 

(a)                                 The closing of the sale of the Transferred
Assets to the Purchaser and the other Transactions contemplated by this
Agreement (the “Closing”) shall take place immediately following the execution
and delivery of this Agreement.

 

(b)                                 At the Closing, the Seller shall cause to be
delivered to the Purchaser:

 

(i)                                    a Bill of Sale and Assignment Agreement,
in substantially the form of Exhibit B, duly executed by the Seller;

 

(ii)                                evidence satisfactory to the Purchaser of
the requisite approval by the Seller, the board of directors and stockholders of
the Seller of the sale of the Transferred Assets to the Purchaser and the other
Transactions;

 

(iii)                            such bills of sale, endorsements, assignments
and other documents as may (in the reasonable judgment of the Purchaser or its
counsel) be necessary to assign, convey, transfer and deliver to the Purchaser
good and valid title to the Transferred Assets free and clear of any
Encumbrances;

 

3

--------------------------------------------------------------------------------

 

(iv)                             evidence satisfactory to the Purchaser of the
receipts for all Consents for the Transferred Contracts, if applicable;

 

(v)                                 a consent from The Rockefeller University to
the assignment of the Rockefeller License Agreement to the Purchaser, in
substantially the form of Exhibit C hereto;

 

(vi)                             a letter agreement from The Rockefeller
University, in substantially the form of Exhibit D hereto; and

 

(vii)                         a consent from [**], in substantially the form of
Exhibit H hereto; and

 

(viii)                     a waiver and release from each of John W. Ripple,
External GC Law Group and Wilmer Cutler Pickering Hale and Dorr LLP, in
substantially the form of Exhibit I hereto.

 

(c)                                  At the Closing, the Purchaser shall cause
to be delivered to the Seller an Assignment and Assumption Agreement, in
substantially the form of Exhibit E, duly executed by the Purchaser.

 

1.8                               Discharge of Liabilities.  On the Closing
Date, the Seller shall have repaid and discharged all indebtedness for borrowed
money owed by the Seller and all ancillary obligations thereto (including all
interest accrued thereon and all fees, charges or premiums associated
therewith). The Seller shall not make any final distribution of the proceeds
received pursuant to this Agreement until the Seller has discharged (or reserved
reasonably adequate funds to satisfy) all Liabilities of the Seller.

 

2.                                      REPRESENTATIONS AND WARRANTIES OF THE
SELLER.

 

The Seller represents and warrants, to and for the benefit of the Purchaser
Indemnitees, as follows:

 

2.1                               Due Organization; No Subsidiaries;
Capitalization.

 

(a)                                 The Seller is a corporation duly organized,
validly existing and in good standing under the laws of the State of Delaware. 
The Seller is not required to be qualified, authorized, registered or licensed
to do business as a foreign corporation in any jurisdiction other than the
jurisdictions listed in Part 2.1 of the Disclosure Schedule, except where
failure to be qualified would not reasonably be expected to have a Material
Adverse Effect.  The Seller is in good standing as a foreign corporation in each
of the jurisdictions listed in Part 2.1 of the Disclosure Schedule, except where
failure to be qualified would not reasonably be expected to result in a Material
Adverse Effect. The Seller does not have any subsidiaries and does not own,
beneficially or otherwise, any shares or other securities of, or any direct or
indirect interest of any nature in, any other Entity.  The Seller has the power
and authority to own, lease and operate the Transferred Assets and to carry on
the Business as previously conducted and as now being conducted.  The Seller has
not conducted any business under or otherwise used, for any purpose or in any
jurisdiction, any fictitious name, assumed name, trade name or other names,
other than “Centaurus Pharmaceuticals, Inc.”

 

(b)                                 The authorized capital stock of Seller
consists of 60,750,000 shares of Common Stock, of which 1,775,750 shares are
issued and outstanding and 47,750,000 shares of Preferred Stock, all of which
are designated as Series A Preferred Stock and 30,075,000 shares of which are
issued and outstanding.

 

4

--------------------------------------------------------------------------------

 

2.2                               Financial Statements.  The Seller has provided
to the Purchaser the Financial Statements.  The Financial Statements fairly
present the financial position of the Seller as of the dates thereof, consistent
with the books and records of the Seller.  Since the Balance Sheet Date, there
has occurred no event or development which, individually or in the aggregate,
has had, or could reasonably be expected to have in the future, a Material
Adverse Effect.

 

2.3                               Undisclosed Liabilities.

 

(a)                                 The Seller has no Liability (whether known
or unknown, whether absolute or contingent, whether liquidated or unliquidated
and whether due or to become due), except for (i) liabilities reflected or
reserved against on the Balance Sheet, (ii) Liabilities which have arisen since
the Balance Sheet Date in the ordinary course of business and (iii) contractual
and other liabilities incurred in the ordinary course of business which are not
required by generally accepted accounting principles in the United States to be
reflected on a balance sheet, (iv) liabilities which have been incurred in
connection with the transactions contemplated by this Agreement and (v)
liabilities disclosed in Section 2.3 of the Disclosure Schedule.

 

(b)                                 The Seller is not now insolvent, nor will it
be rendered insolvent by any of the Transactions.  As used in this section,
“insolvent” means the debts and other probable Liabilities of an Entity exceed
the sum of the present fair saleable value of the assets of such Entity. 
Immediately after giving effect to the consummation of the Transactions: 
(i) the Seller will be able to pay its Liabilities as they become due in the
usual course of its business; and (ii) the Seller will have assets (calculated
at fair market value) that exceed its Liabilities.

 

2.4                               Intellectual Property.

 

(a)                                 Part 2.4(a) of the Disclosure Schedule
accurately identifies: (i) each item of Registered IP in which the Seller has or
purports to have an ownership interest of any nature (whether exclusively,
jointly with another Person, or otherwise); (ii) the jurisdiction in which such
item of Registered IP has been registered or filed and the applicable
registration or serial number; and (iii) any other Person that has an ownership
interest in such item of Registered IP and the nature of such ownership
interest.

 

(b)                                 Part 2.4(b) of the Disclosure Schedule
accurately identifies: (i) each Contract pursuant to which any Intellectual
Property Right or Intellectual Property that was previously used in or is
currently used in the Business is or has been licensed, sold, assigned, or
otherwise conveyed or provided to the Seller (other than: (A) agreements between
the Seller and its employees in the Seller’s standard form thereof and (B)
non-exclusive licenses to third-party software that (1) are not incorporated
into, or used in the development, manufacturing, testing, distribution or
support of, any Transferred Asset and that are not otherwise material to the
Business; and (2) that are generally available to the public and impose no
future monetary obligation on the Seller); and (ii) whether the licenses or
rights granted to Seller in each such Contract are exclusive or non-exclusive
(the “Third-Party IP”).  The Seller has made available to the Purchaser accurate
and complete copies of each Contract identified or required to be identified in
Part 2.4(b) of the Disclosure Schedule.

 

(c)                                  Part 2.4(c) of the Disclosure Schedule
accurately identifies each Contract pursuant to which any Person has been
granted any license under, or otherwise has received or acquired any right
(whether or not currently exercisable) or interest in, any Transferred Product
or Transferred IP.

 

(d)                                 Part 2.4(d) of the Disclosure Schedule
contains a complete and accurate list and summary of all royalties, fees,
commissions, and other amounts payable by the Seller to any other Person

 

5

--------------------------------------------------------------------------------

 

(other than sales commissions paid to employees according to the Seller’s
standard commissions plan) upon or for the manufacture, sale, or distribution of
any Transferred Product or the use of any Transferred IP.

 

(e)                                  The Seller has made available to the
Purchaser a complete and accurate copy of each standard form of Contract related
to Intellectual Property or Intellectual Property Rights used by the Seller at
any time in connection with the Business, including each standard form of:
(i) employee agreement containing any assignment or license of Intellectual
Property Rights; (ii) consulting or independent contractor agreement containing
any intellectual property assignment or license of Intellectual Property Rights;
and (iii) confidentiality or nondisclosure agreement.

 

(f)                                   The Seller exclusively owns all right,
title, and interest to and in the Transferred IP free and clear of any
Encumbrances (other than licenses and rights granted pursuant to the Contracts
identified in Part 2.4(b) of the Disclosure Schedule). The Seller has a valid
right to use and otherwise exploit, and to license others to use and otherwise
exploit, all Third-Party IP identified or required to be identified in
Part 2.4(b) of the Disclosure Schedule.  Without limiting the generality of the
foregoing:

 

(i)                                    All documents and instruments necessary
to establish, perfect, and maintain the rights of the Seller in the Transferred
IP have been validly executed, delivered, and filed in a timely manner with the
appropriate Governmental Body.

 

(ii)                                Each Person who is or was involved in the
creation or development of any Transferred Product or Transferred IP, including
but not limited to any Person who is or was an employee or contractor of the
Seller, has signed a valid, enforceable agreement containing an assignment of
Intellectual Property Rights pertaining to such Transferred Product or
Transferred IP to the Seller and confidentiality provisions protecting the
Transferred IP.

 

(iii)                            The Seller is not bound by, and no Transferred
IP is subject to any Contract containing any covenant or other provision that
limits or restricts the ability of the Seller to use, exploit, assert, or
enforce any Transferred IP.

 

(iv)                             The Seller has taken reasonable measures to
maintain the confidentiality of and otherwise protect and enforce their rights
in all proprietary information pertaining to the Transferred IP.

 

(v)                                 The Transferred IP constitutes, and,
immediately after the Closing the Purchaser will have, all Intellectual Property
Rights used in the conduct of the Business as was previously conducted by the
Seller.

 

(g)                                 All issued Patent Rights included in the
Transferred IP are subsisting, and, to the Knowledge of the Seller, all such
issued Patent Rights are valid and enforceable.  All other Transferred IP is
subsisting, and, to the Knowledge of the Seller, such other Transferred IP is
valid and enforceable. Without limiting the generality of the foregoing:

 

(i)                                    Each item of Transferred IP that is
Registered IP is in compliance with all Legal Requirements and all filings,
payments, and other actions required to be made or taken to maintain such item
of Transferred IP in full force and effect have been made by the applicable
deadline.

 

(ii)                                No interference, opposition, reissue,
reexamination, or other Proceeding is or has been pending or, to the Knowledge
of the Seller, threatened, in which the scope, validity, or

 

6

--------------------------------------------------------------------------------

 

enforceability of any Transferred IP is being, has been, or could reasonably be
expected to be contested or challenged.

 

(h)                                 To the Knowledge of the Seller, no Person
has infringed, misappropriated, or otherwise violated, and no Person is
currently infringing, misappropriating, or otherwise violating, any Transferred
IP.

 

(i)                                    To the Knowledge of the Seller, the
Seller has never infringed (directly, contributorily, by inducement, or
otherwise), misappropriated, or otherwise violated or made unlawful use of any
Intellectual Property Right of any other Person or engaged in unfair
competition.  The development, use or sale of the [**] Product or the sIVIG
Product (each as defined in Exhibit F hereto) are not covered or claimed by any
issued and in force patent that is not owned or controlled by the Seller through
the Transferred IP.  Notwithstanding any other provision of this Agreement, the
Purchaser acknowledges and agrees that the Seller will not be liable to the
Purchaser or to any Purchaser Indemnitees for any third-party claims related to
any of the patents or patent applications identified in Part 2.4(i) of the
Disclosure Schedule or any domestic or foreign counterparts of such patents or
patent applications.

 

(j)                                    There are no pending, nor has there been
any written notice of any, threatened actions, suits, proceedings claims or
allegations by Persons that the Seller is or will be infringing, violating or
unlawfully using any Intellectual Property Rights of any other Person.  Without
limiting the generality of the foregoing:

 

(i)                                    No infringement, misappropriation, or
similar claim or Proceeding involving or relating to any Transferred IP or any
Transferred Product is pending or threatened against the Seller or, to the
Knowledge of the Seller, against any other Person who is or may be entitled to
be indemnified, defended, held harmless, or reimbursed by the Seller with
respect to such claim or Proceeding.  The Seller has never received any notice
or other communication (in writing or otherwise) relating to any actual,
alleged, or suspected infringement, misappropriation, or violation by the
Seller, any of its employees or agents, or any Transferred IP or Transferred
Product of any Intellectual Property Rights of another Person, including any
letter or other communication suggesting or offering that the Seller obtain a
license to any Intellectual Property Right of another Person.

 

(ii)                                No claim or Proceeding involving any
Intellectual Property or Intellectual Property Right licensed to the Seller in
connection with the Business or any of the Transferred Assets is pending or has
been threatened.

 

2.5                               Contracts.

 

(a)                                 Part 1.1(c) of the Disclosure Schedule
identifies each Transferred Contract.  The Seller has made available to the
Purchaser accurate and complete copies of all Seller Contracts.

 

(b)                                 With respect to each of the Contracts
identified in Part 1.1(c) of the Disclosure Schedule, except as disclosed in
Section 2.5 of the Disclosure Schedule: (i) the Seller has not (and, to the
Knowledge of the Seller, no other Person has) violated or breached, or declared
or committed any default under, any such Contract; (ii) no event has occurred,
and no circumstance or condition exists, that would (with or without notice or
lapse of time) result in a violation, breach or default by the Seller (or, to
the Knowledge of the Seller, by any other Person) of or under any of the
provisions of any such Contract; (iii) the Seller has not received any notice or
other communication (in writing or otherwise) regarding any actual or alleged
violation or breach of, or default under, any such Contract; and (iv) the Seller
has not waived any material right under any such Contract.

 

7

--------------------------------------------------------------------------------

 

2.6                               Title to Transferred Assets.  The Seller owns,
and has good and valid title to all of the Transferred Assets, free and clear of
any Encumbrances.

 

2.7                               Tax Matters.  All Taxes required to have been
paid, or claimed by any Governmental Body to be payable, by the Seller have been
duly paid in full on a timely basis.  No claim or other Proceeding is pending
or, to the Knowledge of the Seller, has been threatened in respect of any Tax. 
There are no unsatisfied Liabilities for Taxes, whether with respect to any
notice of deficiency or similar document received by or on behalf of the Seller
or otherwise, except Liabilities for Taxes being contested in good faith by
appropriate proceedings or Taxes not yet due and payable. The Seller has not
been informed in writing that any company return relating to Taxes is being
audited by any Governmental Body.

 

2.8                               Proceedings; Orders.  There is no pending
Proceeding against or involving the Seller, and no Person has threatened to
commence any Proceeding against or involving the Seller. There is no Order to
which any of the Transferred Assets is subject.  To the Knowledge of the Seller,
there is no proposed Order that, if issued or otherwise put into effect:
(i) would have an adverse effect on any of the Transferred Assets or on the
ability of the Seller to comply with or perform any covenant or obligation under
any of the Transactional Agreements; or (ii) would have the effect of
preventing, delaying, making illegal or otherwise interfering with any of the
Transactions. To Seller’s Knowledge, no event has occurred, and no claim,
dispute or other condition or circumstance exists, that would reasonably be
expected to give rise to or serve as a basis for the commencement of any such
Legal Proceeding.

 

2.9                               Compliance with Laws; Regulatory Matters.

 

(a)                                 The Seller has complied in all material
respects with, is not in violation of, and has not received any notices of
violation with respect to, any Legal Requirements.

 

(b)                                 The Seller has made available to the
Purchaser all information and data known to the Seller relating to the safety,
efficacy or toxicity of any Product.

 

2.10                        Authority; Binding Nature of Agreements.  The Seller
has the corporate right, power and authority to enter into and to perform its
obligations under each of the Transactional Agreements to which it is or may
become a party (the “Seller Transactional Agreements”); and the execution,
delivery and performance by the Seller of the Seller Transactional Agreements
have been duly authorized by all necessary action on the part of the Seller and
its managers and members.  The Seller Transactional Agreements constitute the
legal, valid and binding obligations of the Seller, enforceable against the
Seller in accordance with their terms, subject to: (i) laws of general
application relating to bankruptcy, insolvency and the relief of debtors; and
(ii) general principles of equity (the “Enforceability Exceptions”).  The
affirmative vote of the holders of at least sixty percent (60%) of the
outstanding Series A Preferred Stock of the Seller are the only votes of the
equity holders of the Seller necessary to adopt this Agreement and approve the
Transactions.

 

2.11                        Non-Contravention; Consents.  The execution and
delivery by the Seller of any of the Transactional Agreements, or the
consummation or performance by the Seller of any of the Transactions, will not
(with or without notice or lapse of time):

 

(a)                                 contravene, conflict with or result in a
violation of: (i) any of the provisions of the organizational documents of the
Seller; or (ii) any resolution adopted by the board of directors or stockholders
of the Seller;

 

(b)                                 contravene, conflict with or result in a
violation of any Legal Requirement or any Order to which the Seller or any of
the Transferred Assets, is subject;

 

8

--------------------------------------------------------------------------------

 

(c)                                  contravene, conflict with or result in a
violation of any of the terms or requirements of, or give any Governmental Body
the right to revoke, withdraw, suspend, cancel, terminate or modify, any
Governmental Authorization that relates to the Transferred Assets;

 

(d)                                 result in the imposition or creation of any
Encumbrance upon or with respect to any Transferred Asset; or

 

(e)                                  contravene, conflict with or result in a
violation or breach of, or result in a default under, any provision of any
material Contract to which the Seller is a party or by which the Seller (or any
of the Transferred Assets) are bound, or give any Person the right to:
(i) declare a default or exercise any remedy under any such Contract;
(ii) accelerate the maturity or performance of any such Contract; or
(iii) cancel, terminate or modify any such Contract.

 

Except for any such filings, notices or Consents that have been made or obtained
prior to the date of this Agreement, all of which are identified in Section 1.7
of this Agreement, the Seller was not, is not nor will be required to make any
filing with or give any notice to, or to obtain any Consent from, any Person in
connection with the execution and delivery by the Seller of any of the
Transactional Agreements or the consummation or performance by the Seller of any
of the Transactions.

 

2.12                        Related Party Transactions.  Except as set forth in
Part 2.12 of the Disclosure Schedule: (a) no Related Party has, and no Related
Party has had, any interest in any material asset used in or otherwise relating
to the Business; (b) no Related Party is, or has been, indebted to the Seller
(other than for ordinary travel advances); (c) no Related Party has entered
into, or has had any financial interest in, any material Contract, transaction
or business dealing or involving the Seller; (d) to the Knowledge of the Seller,
no Related Party is competing, or has at any time competed, with the Seller; and
(e) no Related Party has any claim or right against the Seller (other than
rights as an equity holder or licensor or rights to receive compensation for
services performed as an employee of the Seller or rights to receive
compensation for services performed as an consultant to the Seller, other rights
arising in the ordinary course of employment or other rights arising in the
ordinary course of consulting).

 

2.13                        No Subsidies.  The Seller does not possess (or has
ever possessed) or have any rights or interests with respect to (or has ever had
any rights or interests with respect to) any grants, incentives or subsidies
from any Governmental Body.

 

2.14                        Environmental Matters. The Seller is in material
compliance with, and is not in material violation of, and has not received any
written notice alleging any material violation by it with respect to any
applicable Environmental Law.

 

2.15                        Employees and Employee Benefits.  The Seller has
complied with all federal, state and local laws relating to the hiring and
classification of employees and independent contractors and the employment of
labor, including provisions thereof relating to wages, hours, equal opportunity,
collective bargaining and the payment of social security and other Taxes.  The
Seller is not delinquent in payments to any of its employees or independent
contractors for any wages, salaries, commissions, bonuses or other direct
compensation for any services performed by them or amounts required to be
reimbursed to such employees or independent contractors and upon any termination
of the employment of any such employees or any termination of status of any
independent contractor.

 

2.16                        Brokers.  The Seller has not agreed or become
obligated to pay, and the Seller has not taken any action that would reasonably
be expected to result in any Person claiming to be entitled to receive, any
brokerage commission, finder’s fee or similar commission or fee in connection
with any of the Transactions.

 

9

--------------------------------------------------------------------------------

 

2.17                        Full Disclosure.  Neither this Agreement nor the
Disclosure Schedule contains any untrue statement of material fact; and neither
this Agreement nor the Disclosure Schedule omits to state any material fact
necessary to make any of the representations, warranties or other statements or
information contained therein, in light of the circumstances in which it was
made, not misleading.  All of the information set forth in the Disclosure
Schedule is accurate and complete in all material respects.

 

3.                                      REPRESENTATIONS AND WARRANTIES OF THE
PURCHASER.

 

The Purchaser represents and warrants, to and for the benefit of the Seller, as
follows:

 

3.1                               Due Organization.  The Purchaser is a
corporation duly organized, validly existing and in good standing under the laws
of the State of Delaware. The Purchaser has the power and authority to carry on
its business as now being conducted by the Purchaser.

 

3.2                               Authority; Binding Nature of Agreements. The
Purchaser has the corporate right, power and authority to enter into and to
perform its respective obligations under each Transactional Agreement to which
it is or may become a party, and the execution and delivery by the Purchaser of
each Transactional Agreement to which the Purchaser is or may become a party has
been duly authorized by all necessary action on the part of the Purchaser and
its respective boards of directors. This Agreement and each other Transactional
Agreement to which the Purchaser is a party constitutes the legal, valid and
binding obligation of the Purchaser enforceable against the Purchaser in
accordance with its terms, subject to the Enforceability Exceptions.

 

3.3                               Non-Contravention; Consents.  Neither the
execution and delivery by the Purchaser of any of the Transactional Agreements,
nor the consummation or performance by the Purchaser of any of the Transactions,
will (with or without notice or lapse of time):

 

(a)                                 contravene, conflict with or result in a
violation of: (i) any of the provisions of the certificate of incorporation or
bylaws of the Purchaser; or (ii) any resolution adopted by the stockholders,
board of directors or any committee of the board of directors of the Purchaser; 
or

 

(b)                                 contravene, conflict with or result in a
violation of any Legal Requirement or any Order to which the Purchaser is
subject.

 

The Purchaser is not nor will be required to make any filing with or give any
notice to, or to obtain any Consent from, any Person in connection with the
execution and delivery by the Purchaser of any of the Transactional Agreements
or the consummation or performance by the Purchaser of any of the Transactions.

 

3.4                               Brokers.  The Purchaser has not agreed or
become obligated to pay, and the Purchaser has not taken any action that would
reasonably be expected to result in any Person claiming to be entitled to
receive, any brokerage commission, finder’s fee or similar commission or fee in
connection with any of the Transactions.

 

4.                                      INDEMNIFICATION, ETC.

 

4.1                               Survival of Representations and Warranties.

 

(a)                                 Subject to Section 4.1(b), the
representations and warranties of the Seller and the Purchaser set forth in this
Agreement shall survive the Closing and the consummation of the transactions
contemplated hereby and continue until the date twenty-four (24) months after
the Closing Date, at which time they shall expire; provided, however, that the
representations and warranties of the Seller set forth in

 

10

--------------------------------------------------------------------------------

 

Sections 2.1(a), 2.4, 2.6, 2.10 and 2.16 and the representations and warranties
of the Purchaser set forth in Sections 3.1, 3.2 and 3.4 shall terminate upon the
expiration of the relevant statute of limitations, taking into account
extensions thereof; provided further, that if a Notice of Claim (as defined on
Schedule 4.4) relating to any representation or warranty set forth in Section 2
or Section 3 is given to the Seller or to the Purchaser, as the case may be, on
or prior to the applicable expiration date of such representation or warranty,
then, notwithstanding anything to the contrary contained in this Section 4.1(a),
such representation or warranty shall not so expire, but rather shall remain in
full force and effect until such time as each and every Claim that is based
upon, or that relates to, any breach of such representation or warranty has been
fully and finally resolved.

 

(b)                                 Notwithstanding anything to the contrary
contained in Section 4.1(a), the limitations set forth in Section 4.1(a) shall
not apply in the case of claims based upon intentional misrepresentation or
fraud.

 

(c)                                  The representations, warranties, covenants
and obligations of the Seller and the Purchaser and the rights and remedies that
may be exercised by the Indemnitees, shall not be limited or otherwise affected
by or as a result of any information furnished to, or any investigation made by
or any knowledge of, any of the Indemnitees or any of their Representatives.

 

(d)                                 For purposes of this Agreement, each
statement or other item of information set forth in the Disclosure Schedule
shall be deemed to be a representation and warranty made by the Seller in this
Agreement.

 

4.2                               Indemnification.

 

(a)                                 Subject to the terms and conditions of this
Section 4, from and after the Closing, the Seller shall indemnify the Purchaser
Indemnitees in respect of, and hold the Purchaser Indemnitees harmless against,
and compensate and reimburse each of the Purchaser Indemnitees for, all Damages
incurred or suffered by the Purchaser Indemnitees resulting from or
constituting:

 

(i)                              any breach of a representation or warranty of
the Seller contained in this Agreement (without giving effect to any materiality
or similar qualification limiting the scope of such representation or warranty);

 

(ii)                          any failure by the Seller to perform any covenant
or agreement contained in this Agreement or any Ancillary Agreement;

 

(iii)                      any Liability of the Seller, other than the Assumed
Liabilities;

 

(iv)                       any Claim by any stockholder or creditor of Seller
against the Purchaser relating to this Agreement or any Transactional Agreements
and the Transactions consummated hereby or thereby; or

 

(v)                            any Proceeding relating to any breach, alleged
breach, Liability or matter of the type referred to in clause “(i),” clause
“(ii),” clause “(iii),” or clause “(iv)”  (including any Proceeding commenced by
any Purchaser Indemnitee for the purpose of enforcing any of its rights under
this Section 4).

 

(b)                                 Subject to the terms and conditions of this
Section 4, from and after the Closing, the Purchaser shall indemnify the Seller
Indemnitees in respect of, and hold the Seller Indemnitees

 

11

--------------------------------------------------------------------------------

 

harmless against, any and all Damages incurred or suffered by the Seller
Indemnitees resulting from or constituting:

 

(i)                                    any breach of a representation or
warranty of the Purchaser contained in this Agreement;

 

(ii)                                any failure by the Purchaser to perform any
covenant or agreement contained in this Agreement or any Ancillary Agreement;

 

(iii)                            any Assumed Liabilities;

 

(iv)                             any Claim by any stockholder or creditor of the
Purchaser against the Seller relating to this Agreement or any Transactional
Agreements and the Transactions consummated hereby or thereby; or

 

(v)                                 any Proceeding relating to any breach,
alleged breach, Liability or matter of the type referred to in clause “(i),”
clause “(ii),” clause “(iii)”, or clause “(iv)” (including any Proceeding
commenced by any Seller Indemnitee for the purpose of enforcing any of its
rights under this Section 4).

 

(c)                                  Notwithstanding anything to the contrary
contained in this Agreement, the following limitations shall apply to
indemnification claims under this Agreement:

 

(i)                                    the Seller shall be liable with respect
to claims under Section 4.2(a)(i) for only that portion of the aggregate Damages
related to such claims, considered together, which exceed $50,000;

 

(ii)                                the aggregate liability of the Seller for
all Damages under Section 4.2(a)(i) shall not exceed the Indemnification Cap;

 

(iii)                            the Purchaser shall be liable with respect to
claims under Section 4.2(b)(i) for only that portion of the aggregate Damages
related to such claims, considered together, which exceed $50,000; and

 

(iv)                             the aggregate liability of the Purchaser for
all Damages under Section 4.2(b)(i) shall not exceed the Indemnification Cap;

 

provided, however, that the limitations set forth in Sections 4.2(c)(i) and
(ii) shall not apply to claims of breach of the representations or warranties of
the Seller under Sections 2.1(a), 2.6, 2.10 and 2.16, and the limitations set
forth in Sections 4.2(c)(iii) and (iv) shall not apply to claims of breach of
the representations or warranties of the Purchaser under Sections 3.1, 3.2 and
3.4.

 

(d)                                 The limitations set forth in
Section 4.2(c) shall not apply to any claim by an Indemnitee for intentional
misrepresentation or fraud. Setoff against the Milestone Payments shall be the
Purchaser Indemnitees’ sole and exclusive remedy for monetary Damages with
respect to an inaccuracy in or breach of the representations and warranties of
the Seller contained in this Agreement.  Notwithstanding anything to the
contrary contained in this Agreement, nothing in this Agreement shall limit or
restrict in any manner whatsoever any remedy (under this Agreement, under
applicable law, in equity or otherwise) of any Purchaser Indemnitee or Seller
Indemnitee against any Person relating to or arising from any intentional
misrepresentation or fraud.

 

12

--------------------------------------------------------------------------------

 

4.3                               Defense of Third-Party Claims.  All claims for
indemnification made under this Agreement resulting from, related to or arising
out of a third-party claim against an Indemnified Party shall be made in
accordance with the following procedures.  An Indemnified Party shall give
prompt written notification to the Indemnifying Party of the commencement of any
action, suit or proceeding relating to a third-party claim for which
indemnification may be sought or, if earlier, upon the assertion of any such
claim by a third party.  Such notification shall include a description in
reasonable detail (to the extent known by the Indemnified Party) of the facts
constituting the basis for such third-party claim and the amount of the Damages
claimed.  Within 15 days after delivery of such notification, the Indemnifying
Party may, upon written notice thereof to the Indemnified Party, assume control
of the defense of such action, suit, proceeding or claim at its sole cost and
expense with counsel reasonably satisfactory to the Indemnified Party; provided
that (i) the Indemnifying Party may only assume control of such defense if it
acknowledges in writing to the Indemnified Party that any Damages or other
Liabilities that may be assessed against the Indemnified Party in connection
with such third-party claim constitute Damages for which the Indemnified Party
shall be indemnified pursuant to this Section 4 and (ii) the Indemnifying Party
may not assume control of the defense of a third-party claim involving criminal
liability or in which equitable relief is sought against the Indemnified Party.
If the Indemnifying Party does not, or is not permitted under the terms hereof
to, so assume control of such defense, the Indemnified Party shall control such
defense.  The Party not controlling such defense may participate therein at its
own expense; provided that if the Indemnifying Party assumes control of such
defense and the Indemnified Party reasonably concludes, based on advice from
counsel, that the Indemnifying Party and the Indemnified Party have conflicting
interests with respect to such action, suit, proceeding or claim, the reasonable
fees and expenses of counsel to the Indemnified Party solely in connection
therewith shall be considered “Damages” for purposes of this Agreement;
provided, however, that in no event shall the Indemnifying Party be responsible
for the fees and expenses of more than one counsel for all Indemnified Parties. 
The party controlling such defense shall keep the other party advised of the
status of such action, suit, proceeding or claim and the defense thereof and
shall consider recommendations made by the other party with respect thereto. 
The Indemnified Party shall not agree to any settlement of, or the entry into
judgment arising from, any such action, suit, proceeding or claim without the
prior written consent of the Indemnifying Party, which shall not be unreasonably
withheld, conditioned or delayed. The Indemnifying Party shall not agree to any
settlement of such action, suit, proceeding or claim that does not include a
complete release of the Indemnified Party from all liability with respect
thereto or that imposes any liability or obligation on the Indemnified Party
without the prior written consent of the Indemnified Party, which shall not be
unreasonably withheld, conditioned or delayed.

 

4.4                               Claim Procedure.   Any claim for
indemnification, compensation or reimbursement pursuant to this Section 4 (and,
at the option of any Indemnitee, any other claim for a monetary remedy, such as
in the case of a claim based upon intentional misrepresentation or fraud,
relating to this Agreement) shall be brought and resolved exclusively in
accordance with Schedule 4.4.

 

5.                                      CERTAIN POST-CLOSING AND OTHER
COVENANTS.

 

5.1                               Achievement of Milestones.  Following the
Closing, the Purchaser shall use Commercially Reasonable Efforts to achieve the
Milestones.

 

5.2                               Further Actions.  From and after the date of
this Agreement for a period of ninety (90) days, the Seller shall cooperate with
the Purchaser and its respective Representatives, and shall execute and deliver
such documents and take such other actions as the Purchaser may reasonably
request to engage John W. Ripple to act on Seller’s behalf; provided, however,
that in the event that Mr. Ripple commences employment or consulting with a
Person other than the Seller during the period thirty (30) to ninety (90) days
following the Closing, the period of cooperation by the Seller set forth in this
Section 5.2 shall cease on the date of such commencement of employment or
consulting. To the extent that the parties

 

13

--------------------------------------------------------------------------------

 

hereto have been unable to obtain any Consent necessary be obtained for the
transfer to the Purchaser of any of the Transferred Assets by the date of this
Agreement:  (a) such Transferred Asset (a “Specified Asset”) shall not be
assigned or transferred to Purchaser until such time as such Consent is
obtained, without any reduction in the Purchase Price under Section 1.3 and
(b) the Seller shall use its reasonable efforts to obtain such Consent as
promptly as practicable thereafter, provided that that the Seller shall not be
required to make any payments or agree to any material undertakings in
connection therewith.  Until such Consent is obtained, Seller shall cooperate,
and shall use its reasonable efforts to cause its Representatives to cooperate,
with the Purchaser in any lawful arrangement designed to provide Purchaser with
the benefits of such Specified Assets at no cost to the Purchaser in excess of
the cost the Purchaser would have incurred (without modification to the terms of
any Contract) if the Consent had been obtained.  If a required Consent with
respect to a Specified Asset is obtained after the Closing Date, the Specified
Asset subject to such Consent shall be deemed to have been assigned and
transferred to the Purchaser as of the date such Consent is effective (and all
references in Section 1.3(a) to the Closing Date shall be deemed to be the
effective date of such Consent with respect to such Specified Asset). The Seller
hereby irrevocably nominates, constitutes and appoints the Purchaser as the true
and lawful attorney-in-fact of the Seller (with full power of substitution)
effective as of the date of this Agreement, and hereby authorizes the Purchaser,
in the name of and on behalf of the Seller, to execute, deliver, acknowledge,
certify, file and record any document, to institute and prosecute any Proceeding
and to take any other action (on or at any time after the date of this
Agreement) that the Purchaser may deem appropriate for the purpose of:
(i) collecting, asserting, enforcing or perfecting any claim, right or interest
of any kind that is included in or relates to any of the Transferred Assets;
(ii) defending or compromising any claim or Proceeding relating to any of the
Transferred Assets; or (iii) otherwise carrying out or facilitating any of the
Transactions.  The power of attorney referred to in the preceding sentence is
and shall be coupled with an interest and shall be irrevocable, and shall
survive the dissolution or insolvency of the Seller.

 

5.3                               Tax Cooperation; Allocation of Taxes.

 

(a)                                 The Seller and the Purchaser agree to
furnish or cause to be furnished to each other, upon request, as promptly as
practicable, such information and assistance relating to the Business or the
Transferred Assets (including access to books and records) as is reasonably
necessary for the filing of all Tax Returns, and the making of any election
related to Taxes, the preparation for any audit by any taxing authority, and the
prosecution or defense of any claim, suit or proceeding relating to any Tax
Return.  The Seller shall retain all books and records with respect to Taxes
pertaining to the Transferred Assets for a period of at least six years
following the Closing.

 

(b)                                 All real property taxes, personal property
taxes and similar ad valorem obligations levied with respect to the Business or
the Transferred Assets for a taxable period that includes (but does not end on)
the date of the Closing shall be apportioned between the Seller and the
Purchaser as of the Closing based on the number of days of such taxable period
ending on the date of the Closing (the “Pre-Closing Tax Period”) and the number
of days of such taxable period after the date of this Agreement (with respect to
any such taxable period, the “Post-Closing Tax Period”).  The Seller shall be
liable for the proportionate amount of such Taxes that is attributable to the
Pre-Closing Tax Period, and the Purchaser shall be liable for the proportionate
amount of such Taxes that is attributable to the Post-Closing Tax Period.  Upon
receipt of any bill for real or personal property Taxes relating to the Business
or the Transferred Assets, the Seller and the Purchaser, as applicable, shall
present a reasonably detailed, written statement to the other setting forth the
amount of reimbursement to which each is entitled under this
Section 5.3(b) together with such supporting evidence as is reasonably necessary
to calculate the proration amount.  The proration amount shall be paid by the
party owing it to the other within 20 days after delivery of such statement.  In
the event that either the Seller or the Purchaser shall make any other payment
for which it is entitled to reimbursement under this Section 5.3(b), the other
party shall make such reimbursement promptly but in no event later than 20 days
after the presentation of a reasonably

 

14

--------------------------------------------------------------------------------

 

detailed, written statement setting forth the amount of reimbursement to which
the presenting party is entitled along with such supporting evidence as is
reasonably necessary to calculate the amount of reimbursement.

 

5.4                               Continuing Access to Information.  Following
the Closing for a period of ninety (90) days, the Seller shall give the
Purchaser and its respective Representatives reasonable access during normal
business hours to (and shall allow the Purchaser and its Representatives to make
copies of) any books and records relating to the Transferred Assets for any
reasonable purpose.

 

5.5                               Publicity.  The Seller and the Purchaser agree
that, on and at all times after the date of this Agreement: (a) no press release
or other publicity concerning any of the Transactions shall be issued or
otherwise disseminated by it or on its behalf without the party’s prior written
consent; and (b) it shall continue to keep the terms of this Agreement and the
other Transactional Agreements strictly confidential; provided, however, that
the Seller and its affiliates may disclose the fact that the Purchaser acquired
the Transferred Assets of the Seller, without disclosing the terms of this
Agreement; provided, further, that the existence and terms of this Agreement and
the other Transactional Agreements may be disclosed to the extent required by
law or pursuant to rules or regulations of any regulatory authority having
jurisdiction over such party, provided that before making such a disclosure,
such party first notifies the Purchaser and gives the Purchaser an opportunity
to limit such disclosure or seek a protective order and cooperates with the
Purchaser as reasonably requested. Notwithstanding the foregoing, the Seller and
Purchaser have agreed on language of a press release in substantially the form
attached hereto as Exhibit G announcing the transaction.

 

5.6                               Noncompetition.  The Seller agrees that from
the Closing Date to the third anniversary of the Closing Date, the Seller shall
not (a) engage directly or indirectly in Competition in any part of the world;
or (b) directly or indirectly be or become an equityholder, owner, co-owner,
affiliate, partner, promoter, agent, representative, designer, consultant,
advisor or manager of, for or to, or otherwise be or become associated with or
acquire or hold any direct or indirect interest in, any person that engages
directly or indirectly in Competition anywhere in the world.

 

5.7                               Development Plan.  The Purchaser shall deliver
an updated Development Plan (as defined in the Rockefeller License Agreement) to
The Rockefeller University within forty-five (45) days after the Closing Date.

 

6.                                      MISCELLANEOUS PROVISIONS.

 

6.1                               Fees and Expenses.

 

(a)                                 The Seller shall bear and pay all fees,
costs and expenses (including fees and expenses of the Seller’s legal,
accounting, financial and other advisors) that have been incurred or that are in
the future incurred by, on behalf of or for the benefit of, the Seller in
connection with: (i) the negotiation, preparation and review of any term sheet
or similar document relating to any of the Transactions; (ii) the negotiation,
preparation and review of this Agreement (including the Disclosure Schedule) and
the other Transactional Agreements; (iii) the preparation and submission of any
filing or notice required to be made or given in connection with any of the
Transactions, and the obtaining of any Consent required to be obtained by the
Seller in connection with any of the Transactions; and (iv) the consummation and
performance of the Transactions.

 

(b)                                 The Purchaser shall bear and pay all fees,
costs and expenses (including fees and expenses of the Purchaser’s legal,
accounting, financial and other advisors) that have been incurred or that are in
the future incurred by, or on behalf or for the benefit of, the Purchaser in
connection with: (i) the

 

15

--------------------------------------------------------------------------------

 

negotiation, preparation and review of any term sheet or similar document
relating to any of the Transactions; (ii) the negotiation, preparation and
review of this Agreement and the other Transactional Agreements; (iii) the
preparation and submission of any filing or notice required to be made or given
in connection with any of the Transactions, and the obtaining of any Consent
required to be obtained by the Purchaser in connection with any of the
Transactions; and (iv) the consummation and performance of the Transactions.

 

6.2                               Attorneys’ Fees.  If any Proceeding relating
to any of the Transactional Agreements or the enforcement of any provision of
any of the Transactional Agreements is brought against any party to this
Agreement, the prevailing party shall be entitled to recover reasonable
attorneys’ fees, costs and disbursements (in addition to any other relief to
which the prevailing party may be entitled).

 

6.3                               Notices.   Any notice or other communication
required or permitted to be delivered to any party under this Agreement shall be
in writing and shall be deemed properly delivered, given and received: (a) when
delivered by hand; (b) if sent by registered, certified or first class mail, the
third business day after being sent; and (c) if sent by overnight delivery via a
national courier service, one business day after being sent, in each case to the
address or electronic mail address set forth beneath the name of such party
below (or to such other address or electronic mail address as such party shall
have specified in a written notice given to the other parties hereto):

 

if to the Purchaser:

 

Momenta Pharmaceuticals, Inc.

675 W. Kendall St.

Cambridge, MA 02142

Attention: General Counsel

 

with a copy to:

 

Cooley LLP

500 Boylston Street

Boston, MA 02116-3736

Attention: Nicole Brookshire

 

if to the Seller:

 

Virdante Pharmaceuticals, Inc.

c/o Clarus Ventures

101 Main Street, Suite 1210

Cambridge, MA 02142

Attention:  John W. Ripple

 

with a copy to:

 

WilmerHale

399 Park Avenue

New York, NY 10022

Attn:  Steven D. Singer

 

6.4                               Headings.  The bold-faced headings contained
in this Agreement are for convenience of reference only, shall not be deemed to
be a part of this Agreement and shall not be referred to in connection with the
construction or interpretation of this Agreement.

 

16

--------------------------------------------------------------------------------

 

6.5                               Counterparts and Exchanges by Electronic
Delivery.  This Agreement may be executed in several counterparts, each of which
shall constitute an original and all of which, when taken together, shall
constitute one agreement. The exchange of a fully executed Agreement (in
counterparts or otherwise) by electronic delivery in .pdf format shall be
sufficient to bind the parties to the terms and conditions of this Agreement.

 

6.6                               Governing Law; Venue.

 

(a)                                 This Agreement shall be construed in
accordance with, and governed in all respects by, the internal laws of the
Commonwealth of Massachusetts (without giving effect to principles of conflicts
of laws).

 

(b)                                 Any Proceeding relating to this Agreement or
the enforcement of any provision of this Agreement must be brought or otherwise
commenced in any state or federal court located in the County of Suffolk,
Massachusetts.  Each party to this Agreement:

 

(i)                                    expressly and irrevocably consents and
submits to the jurisdiction of each state and federal court located in the
County of Suffolk,  Massachusetts (and each appellate court located in the
Commonwealth of Massachusetts) in connection with any such Proceeding;

 

(ii)                                agrees that each state and federal court
located in the County of Suffolk,  Massachusetts shall be deemed to be a
convenient forum; and

 

(iii)                            agrees not to assert (by way of motion, as a
defense or otherwise), in any such Proceeding commenced in any state or federal
court located in the County of Suffolk, Massachusetts, any claim that such party
is not subject personally to the jurisdiction of such court, that such
Proceeding has been brought in an inconvenient forum, that the venue of such
proceeding is improper or that this Agreement or the subject matter of this
Agreement may not be enforced in or by such court.

 

(c)                                  Notwithstanding the foregoing, the Seller
agrees that if any Proceeding is commenced against any Purchaser Indemnitee by
any Person in or before any court or other tribunal anywhere in the world, then
such Purchaser Indemnitee may proceed against the Seller in or before such court
or other tribunal with respect to any indemnification claim or other claim
arising from or relating to such Proceeding or any of the matters alleged
therein or any of the circumstances giving rise thereto.

 

6.7                               Successors and Assigns; Parties in Interest.

 

(a)                                 This Agreement shall be binding upon: the
Seller and its successors and assigns (if any); the Purchaser and its successors
and assigns (if any).  This Agreement shall inure to the benefit of:  the
Seller; the Purchaser; the other Indemnitees; and the respective successors and
assigns (if any) of the foregoing.

 

(b)                                 The Purchaser shall have the right to assign
this Agreement to an affiliated company or in connection with the merger,
consolidation, sale or transfer of all or substantially all of the business to
which this Agreement relates.  The Seller shall not be permitted to assign any
of its respective rights or delegate any of its respective obligations under
this Agreement without the Purchaser’s prior written consent other than to a
nominee, including but not limited to a liquidating trust, in connection with
the wind down or liquidation of the Seller. Any attempted assignment or
delegation by the Seller in violation of this Section 6.7(b) shall be null and
void.

 

17

--------------------------------------------------------------------------------

 

(c)                                  None of the provisions of this Agreement is
intended to provide any rights or remedies to any Person other than the parties
to this Agreement and the other Indemnitees (and their respective successors and
permitted assigns, if any).  Without limiting the generality of the foregoing:
(i) no employee of the Seller shall have any rights under this Agreement or
under any of the other Transactional Agreements; and (ii) no creditor of the
Seller shall have any rights under this Agreement or any of the other
Transactional Agreements.

 

6.8                               Remedies Cumulative; Specific Performance. 
The rights and remedies of the parties hereto shall be cumulative (and not
alternative).  Each party agrees that: (a) in the event of any breach or
threatened breach by the other party of any covenant, obligation or other
provision set forth in this Agreement, such party shall be entitled (in addition
to any other remedy that may be available to it) to: (i) a decree or order of
specific performance or mandamus to enforce the observance and performance of
such covenant, obligation or other provision; and (ii) an injunction restraining
such breach or threatened breach; and (b) no Person shall be required to provide
any bond or other security in connection with any such decree, order or
injunction or in connection with any related Proceeding.

 

6.9                               Waiver.  No failure on the part of any Person
to exercise any power, right, privilege or remedy under this Agreement, and no
delay on the part of any Person in exercising any power, right, privilege or
remedy under this Agreement, shall operate as a waiver of such power, right,
privilege or remedy; and no single or partial exercise of any such power, right,
privilege or remedy shall preclude any other or further exercise thereof or of
any other power, right, privilege or remedy.  No Person shall be deemed to have
waived any claim arising out of this Agreement, or any power, right, privilege
or remedy under this Agreement, unless the waiver of such claim, power, right,
privilege or remedy is expressly set forth in a written instrument duly executed
and delivered on behalf of such Person; and any such waiver shall not be
applicable or have any effect except in the specific instance in which it is
given.

 

6.10                        Amendments.  This Agreement may not be amended,
modified, altered or supplemented other than by means of a written instrument
duly executed and delivered on behalf of the parties hereto.

 

6.11                        Severability.  In the event that any provision of
this Agreement, or the application of any such provision to any Person or set of
circumstances, shall be determined to be invalid, unlawful, void or
unenforceable to any extent, the remainder of this Agreement, and the
application of such provision to Persons or circumstances other than those as to
which it is determined to be invalid, unlawful, void or unenforceable, shall not
be impaired or otherwise affected and shall continue to be valid and enforceable
to the fullest extent permitted by law.

 

6.12                        Entire Agreement.  The Transactional Agreements set
forth the entire understanding of the parties relating to the subject matter
thereof and supersede all prior agreements and understandings among or between
any of the parties relating to the subject matter thereof.

 

6.13                        Disclosure Schedule.  The Disclosure Schedule shall
be arranged in separate parts corresponding to the numbered and lettered
sections contained herein permitting such disclosure, and the information
disclosed in any numbered or lettered part shall be deemed to relate to and to
qualify other numbered and lettered sections contained herein to the extent it
is reasonably apparent on the face of the disclosure that such information is
applicable to such other sections.

 

6.14                        Construction.

 

(a)                                 For purposes of this Agreement, whenever the
context requires:  the singular number shall include the plural, and vice versa;
the masculine gender shall include the feminine and

 

18

--------------------------------------------------------------------------------

 

neuter genders; the feminine gender shall include the masculine and neuter
genders; and the neuter gender shall include the masculine and feminine genders.

 

(b)                                 The parties hereto agree that any rule of
construction to the effect that ambiguities are to be resolved against the
drafting party shall not be applied in the construction or interpretation of
this Agreement or to the other Transactional Agreements.  Each of the parties
hereto acknowledges that he or it has received independent legal advice in
connection with the negotiation and execution of this Agreement and the other
Transactional Agreements or has determined that such advice is not necessary.

 

(c)                                  As used in this Agreement, the words
“include” and “including,” and variations thereof, shall not be deemed to be
terms of limitation, but rather shall be deemed to be followed by the words
“without limitation.”

 

(d)                                 Except as otherwise indicated, all
references in this Agreement and the Exhibits to this Agreement to “Sections,”
“Exhibits” and “Schedules” are intended to refer to Sections of this Agreement,
Exhibits to this Agreement and Schedules to this Agreement.

 

[Remainder of page intentionally left blank]

 

19

--------------------------------------------------------------------------------

 

The parties to this Agreement have caused this Agreement to be executed and
delivered as of the date first written above.

 

 

MOMENTA PHARMACEUTICALS, INC.,

 

a Delaware corporation

 

 

 

 

 

 

By:

/s/ Craig A. Wheeler

 

Name:

Craig A. Wheeler

 

Title:

President and Chief Executive Officer

 

 

 

 

 

VIRDANTE PHARMACEUTICALS, INC.,

 

a Delaware corporation

 

 

 

 

 

 

By:

/s/ John W. Ripple

 

Name:

John W. Ripple

 

Title:

Chief Executive Officer

 

ASSET PURCHASE AGREEMENT
SIGNATURE PAGE

--------------------------------------------------------------------------------

 

EXHIBIT A

 

CERTAIN DEFINITIONS

 

For purposes of the Agreement (including this Exhibit A):

 

Agreement.  “Agreement” shall mean the Asset Purchase Agreement to which this
Exhibit A is attached (including the Disclosure Schedule), as it may be amended
from time to time.

 

Balance Sheet.  “Balance Sheet” shall mean the unaudited balance sheet of the
Seller for the six months ended September 30, 2011.

 

Balance Sheet Date.  “Balance Sheet Date” shall mean September 30, 2011.

 

Books and Records.  “Books and Records” means all files, documents, instruments,
papers of Seller other than the Transferred Records.

 

Business.  “Business” shall mean the Seller’s research and development business
related to the Products.

 

Claim.  “Claim” shall mean and include all past, present and future disputes,
claims, controversies, demands, rights, obligations, liabilities, actions and
causes of action of every kind and nature, including:  (a) any unknown,
inchoate, unsuspected or undisclosed claim; and (b) any claim, right or cause of
action based upon any breach of any express, implied, oral or written contract
or agreement.

 

Commercially Reasonable Efforts. “Commercially Reasonable Efforts” shall mean
with respect to the Purchaser, such efforts that are consistent with the efforts
and resources normally used by the Purchaser in the exercise of its reasonable
business discretion for a product in the Purchaser’s pipeline of similar market
potential at a similar stage in its product life, taking into account issues of
patent coverage, safety and efficacy, product profile, the competitiveness of
the marketplace, the proprietary positions of the Transferred Assets and third
parties, the quality of the clinical data and emerging product profile, the
regulatory structure involved, the profitability of the Transferred Assets, and
other relevant factors, including without limitation, the scientific and
development risk of a project or product, the cost of goods, research and
development costs, alternative discovery and development opportunities that
offer a higher return on investment, and reasonable capital allocation decisions
that take into account the best interests of the Purchaser’s stockholders.

 

Competition.  “Competition” shall mean any business or activity involving or
relating to in any respect (other than an immaterial respect) any aspect of the
engineering, design, development, production, license, manufacture or
distribution of a sialylated IVIG or sialylated [**] compound, product, product
candidate, cell line or constituent thereto.

 

Consent.  “Consent” shall mean any approval, consent, ratification, permission,
waiver or authorization (including any Governmental Authorization).

 

Contract.  “Contract” shall mean any written or oral agreement, contract,
arrangement, instrument, note, guaranty, indemnity, deed, assignment, power of
attorney, certificate, purchase order, work order, insurance policy, benefit
plan, commitment or undertaking of any nature.

 

A-1

--------------------------------------------------------------------------------

 

Damages.  “Damages” shall include any loss, damage, injury, Liability, Claim,
settlement, judgment, award, fine, penalty, Tax, fee (including any legal fee,
expert fee, accounting fee or advisory fee), charge, cost (including any cost of
investigation) or expense of any nature.

 

Disclosure Schedule.  “Disclosure Schedule” shall mean the schedule (dated as of
the date of the Agreement) delivered to the Purchaser on behalf of the Seller.

 

Encumbrance.  “Encumbrance” shall mean any lien, pledge, hypothecation, charge,
mortgage, security interest, encumbrance, claim, right of possession, lease,
tenancy, license, encroachment, Order, option, right of first refusal,
preemptive right, community property interest, defect, impairment, imperfection
of title (including any restriction on the transfer of any asset, any
restriction on the receipt of any income derived from any asset, any restriction
on the use of any asset and any restriction on the possession, exercise or
transfer of any other attribute of ownership of any asset).

 

Entity.  “Entity” shall mean any corporation (including any non-profit
corporation), general partnership, limited partnership, limited liability
partnership, joint venture, estate, trust, cooperative, foundation, society,
political party, union, company (including any limited liability company or
joint stock company), firm or other enterprise, association, organization or
entity.

 

Environment. “Environment” includes:  (a) any and all buildings, structures,
fixtures, fittings, appurtenances, pipes, conduits, valves, tanks, vessels and
containers whether above or below ground level; and (b) ambient air, land
surface, sub-surface strata, soil, surface water, ground water, river sediment,
marshes, wet lands, flora and fauna.

 

Environmental Law.  “Environmental Law” shall mean:  (a) the common law; and
(b) all Legal Requirements, by-laws, orders, instruments, directives, decisions,
injunctions and judgments of any government, local government, international,
supranational, executive, administrative, judicial or regulatory authority or
agency and all approved codes of practice (whether voluntary or compulsory)
relating to the protection of the Environment or of human health or safety or
welfare or to the manufacture, formulation, processing, treatment, storage,
containment, labeling, handling, transportation, distribution, recycling, reuse,
release, disposal, removal, remediation, abatement or clean-up of any
contaminant and any amendment thereto and any and all regulations, orders and
notices made or served thereunder or pursuant thereto).

 

Excluded Assets.  “Excluded Assets” shall mean all assets of the Seller other
than those specifically listed or described in the definition of Transferred
Assets. Without limitation of the foregoing, the Excluded Assets shall include:
(a) all cash and cash equivalents or similar investments, bank accounts,
commercial paper, certificates of deposit, Treasury bills and other marketable
securities; (b) all rights which accrue or will accrue to the benefit of the
Seller under this Agreement or the Transactional Agreements; (c) the Seller’s
corporate name, Virdante Pharmaceuticals; and (d) the Books and Records of the
Seller.

 

Environmental Licenses. “Environmental License” shall mean any Consent or
Governmental Authorization required by or pursuant to any applicable
Environmental Laws.

 

Financial Statements.  “Financial Statements” shall mean the Seller’s audited
balance sheets and related audited statements of income as of December 31, 2008
and 2009 and unaudited balance sheet and related unaudited statement of income
as of December 31, 2010.

 

Governmental Authorization.  “Governmental Authorization” shall mean any:
(a) permit, license, certificate, franchise, concession, approval, consent,
ratification, permission, clearance, confirmation, endorsement, waiver,
certification, designation, rating, registration, qualification or

 

A-2

--------------------------------------------------------------------------------

 

authorization (including all pending applications therefore or renewals thereof)
issued, granted, given or otherwise made available by or under the authority of
any Governmental Body or pursuant to any Legal Requirement; or (b) right under
any Contract with any Governmental Body.

 

Governmental Body.  “Governmental Body” shall mean any: (a) nation,
principality, state, commonwealth, province, territory, county, municipality,
district or other jurisdiction of any nature; (b) federal, state, local,
municipal, foreign or other government; (c) governmental or quasi-governmental
authority of any nature (including any governmental division, subdivision,
department, agency, bureau, branch, office, commission, council, board,
instrumentality, officer, official, representative, organization, unit, body or
Entity and any court or other tribunal); (d) multi-national organization or
body; or (e) individual, Entity or body exercising, or entitled to exercise, any
executive, legislative, judicial, administrative, regulatory, police, military
or taxing authority or power of any nature.

 

Indemnification Cap.  “Indemnification Cap” shall mean the amount equal to
twenty percent (20%) of each Milestone Payment not yet paid by the Purchaser to
the Seller pursuant to Section 1.3 as of the date on which the indemnifiable
loss was incurred (it being agreed that the Seller shall always be entitled to
receive eighty percent (80%) of each such Milestone Payment).

 

Intellectual Property.  “Intellectual Property” shall mean algorithms,
apparatus, databases, data collections, diagrams, formulae, inventions (whether
or not patentable), know-how, logos, marks, methods, processes, proprietary
information, protocols, schematics, specifications, techniques, user interfaces,
URLs, web sites, works of authorship and other forms of technology (whether or
not embodied in any tangible form and including all tangible embodiments of the
foregoing, such as instruction manuals, laboratory notebooks, prototypes,
samples, studies and summaries).

 

Intellectual Property Rights.  “Intellectual Property Rights” shall mean all
past, present, and future rights of the following types, which may exist or be
created under the laws of any jurisdiction in the world: (a) rights associated
with works of authorship, including exclusive exploitation rights, copyrights,
moral rights and mask works; (b) trademark and trade name rights and similar
rights; (c) trade secret rights; (d) patent and industrial property rights;
(e) other proprietary rights in Intellectual Property; and (f) rights in or
relating to registrations, renewals, extensions, combinations, divisions, and
reissues of, and applications for, any of the rights referred to in clauses
“(a)” through “(e)” above.

 

Knowledge.  Knowledge shall mean actual knowledge as of the date hereof of the
Seller’s Chief Executive Officer, John W. Ripple, together with such knowledge
that such individual would be expected to have discovered after reasonable
investigation concerning the existence of the fact or matter in question.

 

Legal Requirement.  “Legal Requirement” shall mean any federal, state, local,
municipal, foreign or other law, statute, legislation, constitution, principle
of common law, resolution, ordinance, code, edict, decree, proclamation, treaty,
convention, rule, regulation, ruling, directive, pronouncement, requirement,
specification, determination, decision, guideline, opinion or interpretation
issued, enacted, adopted, passed, approved, promulgated, made, implemented or
otherwise put into effect by or under the authority of any Governmental Body.

 

Liability.  “Liability” shall mean any debt, obligation, duty or liability of
any nature (including any unknown, undisclosed, unmatured, unaccrued,
unasserted, contingent, indirect, conditional, implied, vicarious, derivative,
joint, several or secondary liability), regardless of whether such debt,
obligation, duty or liability would be required to be disclosed on a balance
sheet prepared in accordance with generally accepted accounting principles in
the United States and regardless of whether such debt, obligation, duty or
liability is immediately due and payable.

 

A-3

--------------------------------------------------------------------------------

 

Material Adverse Effect. “Material Adverse Effect” shall mean any material
adverse change, event, circumstance or development with respect to, or material
adverse effect on, (i) the assets, liabilities, capitalization, financial
condition or results of operations of the Seller or (ii) the ability of the
Purchaser to operate the business of the Seller immediately after the Closing.

 

Order.  “Order” shall mean any: (a) order, judgment, injunction, edict, decree,
ruling, pronouncement, determination, decision, opinion, verdict, sentence,
subpoena, writ or award issued, made, entered, rendered or otherwise put into
effect by or under the authority of any court, administrative agency or other
Governmental Body or any arbitrator or arbitration panel; or (b) Contract with
any Governmental Body entered into in connection with any Proceeding.

 

Patent Rights.  “Patent Rights” shall mean (a) any patents, patent applications,
provisional patent applications and similar instruments; and (b) to the extent
related thereto or derived therefrom, any and all substitutions, reissues,
renewals, extensions, utility models, reexaminations, patents of addition,
supplementary protection certificates, inventors’ certificates, extensions,
requests for continued examinations, designs, divisions, re-filings,
continuations and continuations-in-part thereof, or the like and any foreign
equivalents thereof (including certificates of invention and any applications
therefor) and all documentation associated therewith.

 

Person.  “Person” shall mean any individual, Entity or Governmental Body.

 

Proceeding.  “Proceeding” shall mean any action, suit, litigation, arbitration,
proceeding (including any civil, criminal, administrative, investigative or
appellate proceeding and any informal proceeding), prosecution, contest,
hearing, inquiry, inquest, audit, examination or investigation commenced,
brought, conducted or heard by or before, or otherwise involving, any
Governmental Body or any arbitrator or arbitration panel.

 

Product.  “Product” shall mean any and all compounds, products, product
candidates, cell line or constituent thereof engineered, designed, developed,
licensed or manufactured by, or on behalf of, the Seller, including but not
limited to any proposed products which have previously been or are currently
under pre-clinical development as of the date of this Agreement.

 

Product Materials. “Product Materials” shall mean (a) all inventory of Product
owned or controlled by Seller as of the Closing and (b) all samples or materials
owned or controlled by Seller as of the Closing derived from or used in research
studies of or for a Product.

 

Purchaser Indemnitees.  “Purchaser Indemnitees” shall mean the following
Persons: (a)  the Purchaser; (b) the current and future affiliates of the
Purchaser; (c) the respective Representatives of each the Persons referred to in
clauses (a) and (b) above; the respective successors and assigns of the Persons
referred to in clauses (a), (b) and (c).

 

Registered IP.  “Registered IP” shall mean all Intellectual Property Rights that
are registered, filed or issued under the authority of, with or by any
Governmental Body, including all patents,

 

Related Party.  “Related Party” shall mean: (a) each holder of equity interests
of the Seller; (b) each individual who is an officer or director of the Seller;
(c) each member of the immediate family of each of the individuals referred to
in clauses “(a),” and “(b)” above; and (d) any trust or other Entity in which
any one of the Persons referred to in clauses “(a),” “(b)” and “(c)” above holds
(or in which more than one of such Persons collectively hold), beneficially or
otherwise, a material voting, proprietary or equity interest.

 

A-4

--------------------------------------------------------------------------------

 

Representatives.  “Representatives” shall mean officers, directors, managers,
employees, agents, attorneys, accountants and advisors.

 

Rockefeller License Agreement.  “Rockefeller License Agreement” shall mean the
Second Amended and Restated License Agreement, effective May 7, 2010, by and
between the Seller and The Rockefeller University.

 

Seller Contract.  “Seller Contract” shall mean any Contract:  (a) to which the
Seller is a party; (b) by which the Seller or any of its assets is or may become
bound or under which the Seller has, or may become subject to, any obligation;
or (c) under which the Seller has or may acquire any right or interest.

 

Seller Indemnitees.  “Seller Indemnitees” shall mean the following Persons: (a) 
the Seller; (b) the current affiliates of the Seller; (c) the respective
Representatives of each the Persons referred to in clauses (a) and (b) above;
the respective successors and assigns of the Persons referred to in clauses (a),
(b) and (c) and collectively with the Purchaser Indemnitees (the “Indemnitees”).

 

Tax.  “Tax” shall mean any tax (including any income tax, franchise tax, capital
gains tax, estimated tax, gross receipts tax, value-added tax, surtax, excise
tax, ad valorem tax, transfer tax, stamp tax, sales tax, use tax, property tax,
business tax, occupation tax, inventory tax, occupancy tax, withholding tax or
payroll tax), levy, assessment, tariff, impost, imposition, toll, duty
(including any customs duty), deficiency or fee, and any related charge or
amount in the nature of a tax (including any fine, penalty or interest), that is
or has been (a) imposed, assessed or collected by or under the authority of any
Governmental Body, or (b) payable pursuant to any tax-sharing agreement or
similar Contract.

 

Tax Return.  “Tax Return” shall mean any return (including any information
return), report, statement, declaration, estimate, schedule, notice,
notification, form, election, certificate or other document or information that
is, has been or may be in the future be filed with or submitted to, or required
to be filed with or submitted to, any Governmental Body in connection with the
determination, assessment, collection or payment of any Tax or in connection
with the administration, implementation or enforcement of or compliance with any
Legal Requirement relating to any Tax.

 

Transactional Agreements. “Transactional Agreements” shall mean: (a) the
Agreement; (b) the Bill of Sale and Assignment Agreement; (c) the Assignment and
Assumption Agreement; and (f) all bills of sale, assignments and other
agreements delivered or to be delivered in connection with the transactions
contemplated by the Agreement.

 

Transactions.  “Transactions” shall mean: (a) the execution and delivery of the
Transactional Agreements; and (b) all of the transactions contemplated by the
Transactional Agreements, including: (i) the sale of the Transferred Assets by
the Seller to the Purchaser in accordance with the Agreement; and (ii) the
performance by the Seller and the Purchaser of their respective obligations
under the Transactional Agreements, and the exercise by the Seller and the
Purchaser of their respective rights under the Transactional Agreements.

 

A-5

--------------------------------------------------------------------------------

 

EXHIBIT B

 

FORM OF BILL OF SALE AND ASSIGNMENT AGREEMENT

 

THIS BILL OF SALE AND ASSIGNMENT is made as of December 2, 2011, by VIRDANTE
PHARMACEUTICALS, INC., a Delaware corporation (the “Seller”), for the benefit of
MOMENTA PHARMACEUTICALS, INC., a Delaware corporation (the “Buyer”). 
Capitalized terms used but not defined in this Bill of Sale and Assignment shall
have the meanings given to them in the Purchase Agreement (as defined below).

 

W I T N E S S E T H :

 

WHEREAS, pursuant and subject to the terms and conditions of an Asset Purchase
Agreement of even date herewith, by and between the Seller and the Buyer (the
“Purchase Agreement”), the Seller is causing the Purchased Assets to be sold,
assigned, transferred, conveyed and delivered to the Buyer.

 

WHEREAS, by this instrument, the Seller is vesting in the Buyer all of the
Seller’s right, title and interest in and to the Purchased Assets, free of any
Encumbrances other than Permitted Encumbrances.

 

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency
of which are hereby acknowledged, the Seller hereby sells, assigns, transfers,
conveys and delivers to the Buyer all of  the Seller’s right, title and interest
in and to all the Purchased Assets, free of any Encumbrances other than
Permitted Encumbrances.

 

Nothing contained in this Bill of Sale and Assignment is intended to provide any
rights to the Buyer or the Seller beyond those rights expressly provided to the
Buyer or the Seller in the Purchase Agreement.  Nothing contained in this Bill
of Sale and Assignment is intended to impose any obligations or liabilities on
the Buyer or the Seller beyond those obligations and liabilities expressly
imposed on the Buyer or the Seller in the Purchase Agreement.  Nothing contained
in this Bill of Sale and Assignment is intended to limit any of the rights or
remedies available to the Buyer or the Seller under the Purchase Agreement.
Nothing contained in this Bill of Sale and Assignment shall be deemed to alter
or amend the terms and provisions of the Purchase Agreement, and in the event of
any conflict between the terms and provisions of this Bill of Sale and
Assignment and the Purchase Agreement, the terms and provisions of the Purchase
Agreement shall be deemed to govern and be controlling.

 

This Bill of Sale and Assignment shall be construed in accordance with, and
governed in all respects by, the internal laws of the Commonwealth of
Massachusetts (without giving effect to principles of conflicts of laws).

 

[Remainder of page intentionally left blank]

 

B-1

--------------------------------------------------------------------------------

 

IN WITNESS WHEREOF, the Seller has caused this Bill of Sale and Assignment to be
executed and delivered as of the date first written above.

 

 

 

VIRDANTE PHARMACEUTICALS, INC.,

 

a Delaware corporation

 

 

 

 

 

 

By:

 

 

Name:

John W. Ripple

 

Title:

Chief Executive Officer

 

 

 

 

 

 

 

AGREED AND ACCEPTED:

 

 

 

 

 

 

 

 

MOMENTA PHARMACEUTICALS, INC.,

 

 

 

a Delaware corporation

 

 

 

 

 

 

 

 

 

 

 

 

 

By:

 

 

 

 

Name:

Craig A. Wheeler

 

 

 

Title:

President and Chief Executive Officer

 

 

 

 

[Signature Page to Bill of Sale and Assignment]

 

B-2

--------------------------------------------------------------------------------

 

EXHIBIT C

 

FORM OF CONSENT OF THE ROCKEFELLER UNIVERSITY

 

VIRDANTE PHARMACEUTICALS, INC.
101 Main Street, Suite 1210
Cambridge, MA 02142

 

November 30, 2011

 

Via E-mail and Federal Express

 

Kathleen A. Denis, Ph.D.
Associate Vice President
Office of Technology Transfer
The Rockefeller University
1230 York Avenue, Box 138
New York, NY 10065

 

RE:                          Important Confidential Matter

 

Dear Kathleen:

 

In connection with the Second Amended and Restated License Agreement effective
May 7, 2010 by and between Virdante Pharmaceuticals, Inc.  (“Virdante”) and The
Rockefeller University (“Rockefeller”) (the “License Agreement”), Virdante is
writing to provide information to Rockefeller regarding an important
confidential matter and requests that Rockefeller and Buyer (as defined below)
agree to the terms as set forth herein.  As you know, earlier this year,
Virdante commenced efforts to seek a strategic acquirer or licensor (the
“Strategic Process”) for technology licensed to Virdante from Rockefeller under
the License Agreement and that was the subject of sponsored research under the
Sponsored Research Agreement dated May 7, 2007, as amended, by and between
Virdante and Rockefeller (the “Sponsored Research Agreement”).

 

In connection with the Strategic Process, I am pleased to report that Virdante
is in discussions with Momenta Pharmaceuticals, Inc. (“Buyer”) regarding a
possible transaction in which Buyer proposes to acquire certain assets of
Virdante by means of an asset purchase agreement (the “Transaction”).  Subject
to and upon the closing of the Transaction, Virdante would assign, and Buyer
would assume, the License Agreement as well as the Non-Exclusive Research and
Development Use License Agreement, dated February 10, 2010 by and between
Virdante and Rockefeller and the Letter Agreement by and between Virdante and
Rockefeller, dated November 29, 2011 (the “Ancillary Agreements”).

 

Subject to obtaining your consent and upon the closing of the Transaction,
Virdante will assign to the Buyer all of Virdante’s rights under the License
Agreement and Ancillary Agreements.  In addition, subject to obtaining your
consent and upon the closing of the Transaction, the Buyer will assume all of
Virdante’s obligations pursuant to the License Agreement and the Ancillary
Agreements.

 

C- 1

--------------------------------------------------------------------------------

 

Accordingly, Virdante, Rockefeller and Buyer hereby agree to the terms and
conditions set forth below:

 

1.                                      Buyer Representations:  Buyer represents
to Rockefeller that it accepts the conditions to be legally bound by the License
Agreement and the Ancillary Agreements upon the closing of the Transaction and
to deliver to Rockefeller an updated Development Plan (as defined in the License
Agreement) within forty-five (45) days after the closing date of the proposed
Transaction.

 

2.                                      Rockefeller Consent:  Rockefeller hereby
consents to the assignment of the License Agreement and the Ancillary Agreements
to Buyer upon the closing date of the Transaction.

 

If Rockefeller agrees with these terms and conditions, please have Rockefeller
sign this letter agreement and forward to my attention.

 

Thank you for your attention to this matter.

 

Very truly yours,

 

VIRDANTE PHARMACEUTICALS, INC.

 

 

 

 

 

 

By:

/s/ John W. Ripple

 

Name:

John W. Ripple

 

Title:

Chief Executive Office

 

 

 

 

 

ACKNOWLEDGED AND AGREED:

 

 

 

THE ROCKEFELLER UNIVERSITY

 

 

 

 

 

 

 

 

 

 

By:

/s/ Kathleen A. Denis

 

 

Name:

Kathleen A. Denis, Ph.D.

 

 

Title:

Associate Vice President Technology Transfer

 

 

 

 

 

 

 

 

 

MOMENTA PHARMACEUTICALS, INC.

 

 

By:

 

 

 

Name:

 

 

 

Title:

 

 

 

C- 2

--------------------------------------------------------------------------------

 

Accordingly, Virdante, Rockefeller and Buyer hereby agree to the terms and
conditions set forth below:

 

1.                                      Buyer Representations:  Buyer represents
to Rockefeller that it accepts the conditions to be legally bound by the License
Agreement and the Ancillary Agreements upon the closing of the Transaction and
to deliver to Rockefeller an updated Development Plan (as defined in the License
Agreement) within forty-five (45) days after the closing date of the proposed
Transaction.

 

2.                                      Rockefeller Consent:  Rockefeller hereby
consents to the assignment of the License Agreement and the Ancillary Agreements
to Buyer upon the closing date of the Transaction.

 

If Rockefeller agrees with these terms and conditions, please have Rockefeller
sign this letter agreement and forward to my attention.

 

Thank you for your attention to this matter.

 

Very truly yours,

 

VIRDANTE PHARMACEUTICALS, INC.

 

 

 

 

 

 

By:

 

 

Name:

John W. Ripple

 

Title:

Chief Executive Office

 

 

 

 

 

ACKNOWLEDGED AND AGREED:

 

 

 

THE ROCKEFELLER UNIVERSITY

 

 

 

 

 

 

 

 

 

 

By:

/s/ Kathleen A. Denis

 

 

Name:

Kathleen A. Denis, Ph.D.

 

 

Title:

Associate Vice President Technology Transfer

 

 

 

 

 

 

 

 

 

MOMENTA PHARMACEUTICALS, INC.

 

 

By:

 

 

 

Name:

 

 

 

Title:

 

 

 

 

C- 3

--------------------------------------------------------------------------------

 

EXHIBIT D

 

LETTER AGREEMENT WITH THE ROCKEFELLER UNIVERSITY

 

VIRDANTE PHARMACEUTICALS, INC.
101 Main Street, Suite 1210
Cambridge, MA 02142

 

November 29, 2011

 

Via E-mail and Federal Express

 

Kathleen A Denis, Ph.D.
Associate Vice President
Office of Technology Transfer
The Rockefeller University
1230 York Avenue, Box 138
New York, NY 10065

 

RE:                          Letter Agreement RE License Agreement

 

Dear Kathleen:

 

As we discussed, in connection with (i) the Second Amended and Restated License
Agreement effective May 7, 2010 by and between Virdante Pharmaceuticals, Inc.
(“Virdante”) and The Rockefeller University (“Rockefeller”) (the “License
Agreement”), and (ii) the Sponsored Research Agreement dated May 7, 2007, as
amended, by and between Virdante and Rockefeller (the “Sponsored Research
Agreement”), Virdante and Rockefeller hereby agree as follows:

 

1.                                      Updated Rockefeller Patent Rights.  In
connection with the patents and patentapplications owned by Rockefeller that
were added to the License Agreementunder the terms of the Sponsored Research
Agreement, Virdante and Rockefeller acknowledge and agree that Exhibit A to the
License Agreement is hereby replaced and superseded by the Exhibit A attached to
this Letter Agreement effective as of the date of this Letter Agreement.

 

2.                                      Final Payment under Sponsored Research
Agreement:  In August 2011, in connection with the Sponsored Research Agreement,
Virdante paid the final one-time payment of $[**] to Rockefeller and Virdante’s
payment obligations under the Sponsored Research Agreement have been satisfied
in full.

 

3.                                      2011 Annual License Maintenance Fees. 
In August 2011, Virdante paid the annual license fee of $[**] due on the fourth
anniversary of the License

 

D- 1

--------------------------------------------------------------------------------

 

Agreement.  For avoidance of doubt, Virdante’s obligations under the License
Agreement to pay annual license maintenance fees to Rockefeller on the fifth and
six anniversaries and thereafter under Section 4.3 of the License Agreement
shall remain in full force and effect.

 

4.                                      Misc.  Except as provided, herein the
License Agreement shall remain in full force and effect. The License Agreement
is in effect and in good standing and neither party is aware of any material
breach of the License Agreement on the part of the other party as of the date of
this Letter Agreement.

 

If Rockefeller agrees with these terms and conditions, please have Rockefeller
sign this Letter Agreement and forward to my attention.

 

Thank you for your support of Virdante and your attention to this matter.

 

Very truly yours,

 

VIRDANTE PHARMACEUTICALS, INC.

 

 

 

 

 

 

By:

/s/ John W. Ripple

 

Name:

John W. Ripple

 

Title:

Chief Executive Office

 

 

 

 

 

ACKNOWLEDGED AND AGREED:

 

 

 

THE ROCKEFELLER UNIVERSITY

 

 

 

 

 

 

 

 

 

 

By:

/s/ Kathleen A. Denis

 

 

Name:

Kathleen A. Denis, Ph.D.

 

 

Title:

Associate Vice President Technology Transfer

 

 

D- 2

--------------------------------------------------------------------------------

 

EXHIBIT A

 

ROCKEFELLER PATENT RIGHTS

 

1.                                      All patent rights represented by or
issuing from the patents and patent applications set forth in the attached
listing.

 

D- 3

--------------------------------------------------------------------------------

 

Case Number:

 

Country Name

 

Fox No:

 

Status

 

Application #:

 

Filing Date:

 

Patent #:

 

Issue Date:

 

Family 1

[**]

 

[**]

 

 

 

 

 

 

 

 

 

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

Family 2

[**]

 

[**]

 

 

 

 

 

 

 

 

 

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

[**]

 

[**]

 

[**]

Family 3

[**]

 

[**]

 

 

 

 

 

 

 

 

 

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

 

 

Family 4

 

D- 4

--------------------------------------------------------------------------------

 

[**]

 

[**]

 

 

 

 

 

 

 

 

 

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

Family 5

[**]

 

[**]

 

 

 

 

 

 

 

 

 

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

[**]

 

[**]

 

[**]

 

 

[**]

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

Family 6

[**]

 

[**]

 

 

 

 

 

 

 

 

 

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

Family 7

[**]

 

[**]

 

 

 

 

 

 

 

 

 

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

Family 8

[**]

 

[**]

 

 

 

 

 

 

 

 

 

 

 

 

 

 

[**]

 

[**]

 

[**]

 

 

 

 

 

 

 

 

 

D- 5

--------------------------------------------------------------------------------

 

EXHIBIT E

 

FORM OF ASSIGNMENT AND ASSUMPTION AGREEMENT

 

THIS ASSUMPTION AGREEMENT is made as of December 2, 2011, by and between MOMENTA
PHARMACEUTICALS, INC., a Delaware corporation (the “Purchaser”), and VIRDANTE
PHARMACEUTICALS, INC., a Delaware corporation (the “Seller”).  Capitalized terms
used but not defined in this Assumption Agreement shall have the meanings given
to them in the Purchase Agreement (as defined below).

 

W I T N E S S E T H:

 

WHEREAS, pursuant and subject to the terms and conditions of that certain Asset
Purchase Agreement of even date herewith by and between the Purchaser and the
Seller (the “Purchase Agreement”), the Purchaser is agreeing to assume the
Assumed Liabilities.

 

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency
of which are hereby acknowledged, and subject in all respects to the limitations
set forth in Section 1.4 of the Purchase Agreement, the Purchaser hereby accepts
the assignment of the Seller’s right, title, benefit, privileges and interest in
and to the Assumed Liabilities and all of the Seller’s burdens, obligations and
liabilities in connection with each of the Assumed Liabilities and assumes and
agrees to observe and perform all of the duties, obligations, terms, provisions
and covenants, and to pay and discharge all of the liabilities of the Seller to
be observed, performed, paid or discharged from and after the Closing in
connection with the Assumed Liabilities..

 

Nothing contained in this Assumption Agreement shall be deemed to alter or amend
the terms and provisions of the Purchase Agreement, and in the event of any
conflict between the terms and provisions of this Assumption Agreement and the
Purchase Agreement, the terms and provisions of the Purchase Agreement shall be
deemed to govern and be controlling.

 

Nothing contained in this Assumption Agreement is intended to provide any right
or remedy to any person or entity, other than the Seller and each third party to
each Transferred Contract.  Notwithstanding the foregoing, for the avoidance of
doubt, with respect to matters between the Purchaser and the Seller, the terms
of the Purchase Agreement shall be deemed to govern and be controlling.

 

This Assumption Agreement shall be construed in accordance with, and governed in
all respects by, the internal laws of the Commonwealth of Massachusetts (without
giving effect to principles of conflicts of laws).

 

[Remainder of page intentionally left blank]

 

E-1

--------------------------------------------------------------------------------

 

IN WITNESS WHEREOF, the parties have caused this Assumption Agreement to be
executed and delivered as of the date first written above.

 

 

MOMENTA PHARMACEUTICALS, INC.,

 

a Delaware corporation

 

 

 

 

 

By:

 

 

Name:

Craig A. Wheeler

 

Title:

President and Chief Executive Officer

 

 

 

 

 

VIRDANTE PHARMACEUTICALS, INC.,

 

a Delaware corporation

 

 

 

 

 

By:

 

 

Name:

John W. Ripple

 

Title:

Chief Executive Officer

 

[Signature Page to Assumption Agreement]

 

E-2

--------------------------------------------------------------------------------

 

EXHIBIT F

 

EARN-OUT

 

The following sets forth the various milestones (collectively, the “Milestones”)
for the purposes of determining the Milestones Payments that may become payable
pursuant to Section 1.3(b) of the Agreement.  The Purchaser shall use
Commercially Reasonable Efforts to achieve such Milestones.

 

(a)           “Milestone #1A” means [**];

 

(b)           “Milestone #1B” means [**];

 

(c)           “Milestone #1C” means [**];

 

(d)           “Milestone #2A” means [**];

 

(e)           “Milestone #2B” means [**];

 

(f)            “Milestone #2C” means [**];

 

(g)           “Milestone #3A” means [**];

 

(h)           “Milestone #3B” means [**]; and

 

(i)            “Milestone #3C” means [**].

 

If a Milestone is attained prior to the end of its applicable Milestone
Measuring Period, then within thirty (30) days following the attainment of a
Milestone, the Purchaser shall deliver to the Seller a certificate (the
“Milestone Compliance Certificate”) certifying the date of the satisfaction of
the applicable Milestone and that the Seller is entitled to receive the
applicable Milestone Payment within fifteen (15) days after such Milestone
Compliance Certificate is sent by the Purchaser (the “Milestone Payment Date”).
If a Milestone is not attained on or before the end of the applicable Milestone
Measuring Period, then on or before the date that is thirty (30) days after the
end of the applicable Milestone Measuring Period, the Purchaser shall deliver to
the Seller a certificate certifying the Milestone(s) that have not occurred and
that the Purchaser has complied with its obligations under this Agreement.

 

For purposes of the section above,

 

(a)           “Milestone Measuring Period” shall mean each of the anniversary
dates of the Closing Date specified above by which an applicable Milestone must
be achieved.

 

(b)           “[**] Product” shall mean [**].

 

(c)           “sIVIG Product” shall mean [**].

 

(d)           “Other Sialylated Product” shall mean [**].

 

(e)           “[**] Study” means [**].

 

(f)            “Valid Claim” means (i) a claim of an issued and unexpired patent
included in or related to the Patent Rights transferred pursuant to this
Agreement that (A) has not been rejected, revoked or held

 

F-1

--------------------------------------------------------------------------------

 

to be invalid or unenforceable by a court or other authority of competent
jurisdiction, from which decision no appeal can be further taken, or (B) has not
been finally abandoned, disclaimed or admitted to be invalid or unenforceable
through reissue or disclaimer; or (ii) a claim included in or related to the
Patent Rights transferred pursuant to this Agreement that has not been finally
determined to be unallowable by the applicable governmental authority (from
which no appeal is or can be taken).

 

For the avoidance of doubt, a [**] Product, sIVIG Product or Other Sialylated
Product cannot achieve Milestone Payments in more than one Product category
(e.g., an Initial Product, a Second Product and an Other Sialylated Product);
such Milestone categories are mutually exclusive.

 

F-2

--------------------------------------------------------------------------------

 

EXHIBIT G

 

FORM OF PRESS RELEASE

 

Momenta Pharmaceuticals Acquires Assets From Virdante Pharmaceuticals

 

CAMBRIDGE, Mass., Dec. 5, 2011 (GLOBE NEWSWIRE) - Momenta Pharmaceuticals, Inc.
(Nasdaq:MNTA), a biotechnology company specializing in the characterization and
engineering of complex drugs, today announced that it has signed an agreement to
acquire the Sialic Switch assets of Virdante Pharmaceuticals, Inc., including
intellectual property and cell lines, relating to the sialylation of intravenous
immunoglobulin (IVIG) and other proteins.  Momenta made an upfront payment of
$4.5 million and may make additional contingent milestone payments, which, if
all development and regulatory milestones are achieved, will total $51.5
million.

 

“Virdante’s Sialic Switch technology represents an exciting approach to
potentially regulate anti-inflammatory activity of proteins,” said Ganesh
Venkataraman, Ph.D., Chief Scientific Officer of Momenta Pharmaceuticals, Inc.
“Sialylation complements our existing technology platform and we look forward to
advancing this technology in development programs, including biobetters and
novel products.”

 

Virdante, a venture-backed biotechnology company, was founded in 2008 to apply
its Sialic Switch technology to develop novel therapeutic treatments for
autoimmune and inflammatory disorders.  Virdante’s Sialic Switch technology is
based on the principle of activating a novel anti-inflammatory pathway by
specifically sialylating Fc-linked glycans of lgG antibodies.

 

About Momenta

 

Momenta Pharmaceuticals is a biotechnology company specializing in the detailed
structural analysis of complex mixture drugs.  Momenta is applying its
technology to the development of generic versions of complex drug products, as
well as to the discovery and development of novel drugs.  Momenta was founded in
2001 based on technology initially developed at Massachusetts Institute of
Technology and is headquartered in Cambridge, MA.

 

To receive additional information about Momenta, please visit the website at
www.momentapharma.com, which does not form a part of this press release.  Our
logo, trademarks, and service marks are the property of Momenta
Pharmaceuticals, Inc.  All other trade names, trademarks, or service marks are
property of their respective owners.

 

CONTACT:

Beverly Holley

 

Director, Investor Relations

 

bholley@momentapharma.com

 

617-395-5189

Source: Momenta Pharmaceuticals

 

News Provided by Acquire Media

 

G-1

--------------------------------------------------------------------------------

 

EXHIBIT H

 

FORM OF CONSENT OF [**]

 

VIRDANTE PHARMACEUTICALS, INC.

101 Main Street, Suite 1210

Cambridge, MA 02142

 

November 21, 2011

 

Via E-mail and Federal Express

 

[**]

 

RE:         Important Confidential Matter

 

Dear [**]:

 

In connection with the Small Scale Manufacturing Agreement (the “Agreement”) by
and between [**] and Virdante Pharmaceuticals, Inc. (“Virdante”) effective
June 22, 2011 (the “2011 Agreement”), Virdante is writing to provide information
to [**] regarding an important confidential matter.  As you know, earlier this
year, Virdante commenced efforts to seek a strategic acquirer or licensor (the
“Strategic Process”).

 

In connection with the Strategic Process, I am pleased to report that Virdante
is in discussions with Momenta Pharmaceuticals, Inc. or its affiliate(s) (the
“Buyer”) regarding a possible transaction in which Buyer proposes to acquire all
or substantially all of the assets of Virdante by means an asset purchase
agreement (the “Transaction”).  As you may know, Buyer is a public
pharmaceutical company that develops and/or commercializes therapeutic or
diagnostic products for humans and has a significant market capitalization.  As
a public company, Buyer’s public securities law filings are available at
www.sec.gov.  Buyer’s corporate address and corporate web site are as follows:

 

Momenta Pharmaceuticals, Inc.

675 West Kendall Street

Cambridge, MA 02142

Website:  http://www.momentapharma.com

 

In connection with the Transaction, Buyer has indicated that Virdante would
assign, and Buyer would assume, (i) the 2011 Agreement, (ii) Cell Line
Development Services Agreement by and between Virdante and [**], dated March 31,
2010 (the “2010 Agreement”) and (iii) the Termination Agreement by and between
Virdante and [**] dated June 22, 2011 (the “Termination Agreement”) and together
with the 2011 Agreement and the 2010 Agreement, (the “Agreements”). 
Accordingly, Virdante is writing to provide notice to [**] of the proposed

 

H-1

--------------------------------------------------------------------------------

 

assignment and seeks [**] consent in connection with the assignment of the
Agreements to Buyer.

 

Virdante would ask [**] to formally consent in writing to the proposed
assignment by Virdante, and proposed assumption, of the Agreements in connection
with the Transaction.  Such assignment would (i) enter into force as soon as
Virdante or Momenta notifies [**] that the Transaction has taken place, and if
such notification is not received by [**] by December 31, 2011, the consent from
[**] as expressed through the signature below shall be void, and (ii) even after
such assignment, Virdante shall, in addition to Momenta, still have towards [**]
all obligations on confidentiality, non use of material and information and
granting rights in inventions and in know-how, as agreed in the Agreements.  If
[**]agrees with these terms and conditions, please have [**] sign this Letter
Agreement and forward to my attention.

 

Thank you for your support of Virdante and your attention to this matter.

 

Very truly yours,

 

VIRDANTE PHARMACEUTICALS, INC.

 

 

 

 

 

By:

/s/ John W. Ripple

 

Name:

John W. Ripple

 

Title:

Chief Executive Officer

 

 

 

 

 

ACKNOWLEDGED AND AGREED:

 

 

 

By:

[**]

 

Name:

[**]

 

Title:

CEO

 

 

 

By:

[**]

 

Name:

[**]

 

Title:

Financial Manager

 

 

H-2

--------------------------------------------------------------------------------

 

EXHIBIT I

 

FORM OF WAIVER AND RELEASE

 

December     , 2011

 

Momenta Pharmaceuticals, Inc.

675 W. Kendall St.

Cambridge, MA 02142

 

Ladies and Gentlemen:

 

Reference is made to that certain Asset Purchase Agreement dated as of
December     , 2011 (the “Asset Purchase Agreement), by and between Momenta
Pharmaceuticals, Inc., a Delaware corporation (“Purchaser”) and Virdante
Pharmaceuticals, Inc., a Delaware corporation (the “Company”), pursuant to which
Purchaser will acquire substantially all of the assets of the Company (the
“Transaction”).  As has been relayed to the undersigned, the Purchaser does not
intend to assume the Company’s contract with and obligations to the undersigned
in connection with the Transaction.

 

To induce the Purchaser to execute the Asset Purchase Agreement and to
consummate the Transaction contemplated thereby, and for other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the
undersigned, in his individual capacity, intending to be legally bound, hereby
covenants and agrees as follows:

 

1.             Acknowledgement.  The undersigned participated in the negotiation
of Transaction and is fully aware of all of the details of the Transaction.

 

2.             Waiver.  The undersigned hereby agrees not to assert against and
waives any all Claims against the Purchaser that it may have, whether at law or
in equity and regardless of the legal theory upon which such Claim may be based
(including without limitation based upon any theory of successor liability or
based upon any claim of fraudulent transfer or any other Claim alleging that the
consideration paid in connection with the consummation of the Transaction is
insufficient for any reason), for any failure on the part of the Company to
honor any of the obligations that the Company may have (as a debtor or
otherwise) to the undersigned.

 

3.             Release.  The undersigned hereby irrevocably, unconditionally and
completely releases, acquits and forever discharges each of the Releasees (as
defined below) from any Claim (as defined below), and hereby irrevocably,
unconditionally and completely waives and relinquishes each and every Claim that
the undersigned may have had in the past, may now have or may have in the future
against any of the Releasees, relating to any written or oral agreements or
arrangements by and between the undersigned and the Company occurring, existing
or entered into at any time up to and including the date of this letter
agreement.

 

4.             For purposes of this Agreement:

 

(a)           the term “Releasees” means: (i) the Purchaser; (ii) each affiliate
of the Purchaser; and (iii) the successors and past, present and future assigns,
directors, officers, agents,

 

I-1

--------------------------------------------------------------------------------

 

attorneys and representatives of the respective entities identified or otherwise
referred to in clauses (i) through (ii) of this clause (a); and

 

(b)           the term “Claim” means all past, present and future disputes,
claims, controversies, demands, rights, obligations, liabilities, actions and
causes of action of every kind and nature, including, without limitation:
(i) any unknown, unsuspected or undisclosed claim; and (ii) any claim or right
that may be asserted or exercised by the undersigned.

 

5.             Miscellaneous.  This Setter agreement shall be governed by, and
construed in accordance with, the laws of the Commonwealth of Massachusetts,
regardless of the laws that might otherwise govern under applicable principles
of conflicts of laws.

 

 

 

 

 

 

Name:

 

 

Address:

 

 

 

 

 

 

I-2

--------------------------------------------------------------------------------

 

SCHEDULE 1.1(a)

 

TRANSFERRED IP

 

1.                                      The patents and patent applications set
forth in Appendix 1.1(a) attached hereto are hereby incorporated by reference
into this Schedule 1.1(a).

 

APPENDIX 1.1(a)

 

LIST OF PATENTS

 

[**]

 

 

 

 

 

 

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

[**]

 

 

 

 

 

 

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

[**]

 

[**]

 

 

--------------------------------------------------------------------------------

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

[**]

 

 

 

 

 

 

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

 

[**]

 

 

 

 

 

 

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

 

 

ii

--------------------------------------------------------------------------------

 

[**]

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

 

[**]

 

 

 

 

 

 

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

 

 

iii

--------------------------------------------------------------------------------

 

SCHEDULE 1.1(b)

 

TRANSFERRED TANGIBLE ASSETS

 

1.                                      The tangible personal property set forth
in Appendix 1.1(b) attached hereto is hereby incorporated by reference into this
Schedule 1.1(b).

 

APPENDIX 1.1(b)

 

LISTING OF TANGIBLE ASSETS*

 

Samples

 

Relevant
Agreement

 

Status

 

Visually
inspected by
Purchaser
—

 

Lot #

 

Total
derived from
excel
inventory

 

Temp

 

Physical
count

 

Location
(MASY Box
location)

[**]

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

[**]

 

[**]

[**]

 

[**]

 

[**]

 

[**]

[**]

 

[**]

 

[**]

 

[**]

 

[**]

 

[**]

[**]

 

[**]

 

[**]

 

[**]

[**]

 

[**]

 

[**]

 

[**]

 

[**]

 

[**]

[**]

 

[**]

 

[**]

 

[**]

[**]

 

[**]

 

[**]

 

[**]

 

[**]

 

[**]

[**]

 

[**]

 

[**]

 

[**]

[**]

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

[**]

 

[**]

[**]

 

[**]

 

[**]

 

[**]

[**]

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

[**]

 

[**]

 

 

 

[**]

 

[**]

[**]

 

[**]

 

[**]

 

[**]

[**]

 

[**]

 

[**]

 

 

 

[**]

 

[**]

[**]

 

[**]

 

[**]

 

[**]

 

 

[**]

 

[**]

 

[**]

 

[**]

 

[**]

[**]

 

[**]

 

[**]

 

[**]

 

 

[**]

 

[**]

 

 

 

[**]

 

[**]

[**]

 

[**]

 

[**]

 

[**]

[**]

 

[**]

 

[**]

 

 

 

[**]

 

[**]

[**]

 

[**]

 

[**]

 

[**]

 

 

[**]

 

[**]

 

[**]

 

[**]

 

[**]

[**]

 

[**]

 

[**]

 

[**]

 

 

[**]

 

[**]

 

 

 

[**]

 

[**]

[**]

 

[**]

 

[**]

 

[**]

[**]

 

[**]

 

[**]

 

 

 

[**]

 

[**]

[**]

 

[**]

 

[**]

 

[**]

 

 

[**]

 

[**]

 

[**]

 

[**]

 

[**]

[**]

 

[**]

 

[**]

 

[**]

[**]

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

[**]

 

[**]

 

[**]

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

[**]

 

[**]

 

[**]

[**]

 

[**]

 

 

 

[**]

[**]

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

[**]

 

[**]

[**]

 

[**]

 

[**]

 

[**]

[**]

 

[**]

 

[**]

 

[**]

 

[**]

 

[**]

[**]

 

[**]

 

[**]

 

[**]

[**]

 

[**]

 

[**]

 

[**]

 

[**]

 

[**]

[**]

 

[**]

 

[**]

 

[**]

[**]

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

[**]

 

[**]

 

[**]

[**]

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

[**]

 

[**]

 

[**]

[**]

 

[**]

 

[**]

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

[**]

 

[**]

 

 

 

 

[**]

 

[**]

 

[**]

 

--------------------------------------------------------------------------------

 

[**]

 

[**]

 

[**]

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

[**]

 

[**]

 

 

 

 

[**]

 

[**]

 

[**]

[**]

 

[**]

 

[**]

 

[**]

 

 

 

[**]

[**]

 

[**]

 

[**]

 

[**]

[**]

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

[**]

 

[**]

 

[**]

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

[**]

 

[**]

 

 

 

 

[**]

 

[**]

 

[**]

[**]

 

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

[**]

 

[**]

 

[**]

[**]

 

[**]

 

[**]

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

[**]

 

[**]

 

[**]

[**]

 

[**]

 

[**]

 

[**]

 

 

[**]

 

[**]

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

[**]

 

[**]

 

[**]

[**]

 

[**]

 

[**]

 

[**]

[**]

 

[**]

 

[**]

 

[**]

 

[**]

 

[**]

[**]

 

[**]

 

[**]

 

[**]

 

 

[**]

 

[**]

 

[**]

 

[**]

 

[**]

[**]

 

[**]

 

[**]

 

[**]

 

 

[**]

 

[**]

 

[**]

 

[**]

 

[**]

[**]

 

[**]

 

[**]

 

[**]

 

 

[**]

 

[**]

 

[**]

 

[**]

 

[**]

[**]

 

[**]

 

[**]

 

[**]

 

 

[**]

 

[**]

 

[**]

 

[**]

 

[**]

[**]

 

[**]

 

[**]

 

[**]

[**]

 

[**]

 

[**]

 

[**]

 

[**]

 

[**]

[**]

 

[**]

 

[**]

 

[**]

 

 

[**]

 

[**]

 

[**]

 

[**]

 

[**]

 

 

[**]

 

[**]

 

[**]

 

 

[**]

 

[**]

 

[**]

 

[**]

 

[**]

[**]

 

[**]

 

[**]

 

[**]

 

 

[**]

 

[**]

 

[**]

 

[**]

 

[**]

[**]

 

[**]

 

[**]

 

[**]

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

[**]

 

[**]

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

[**]

 

[**]

 

[**]

[**]

 

[**]

 

 

 

[**]

[**]

 

[**]

 

[**]

 

[**]

 

[**]

 

[**]

[**]

 

[**]

 

 

 

[**]

 

 

[**]

 

[**]

 

[**]

 

[**]

 

[**]

[**]

 

[**]

 

 

 

[**]

 

 

[**]

 

[**]

 

[**]

 

[**]

 

[**]

[**]

 

[**]

 

 

 

[**]

[**]

 

[**]

 

[**]

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

[**]

 

[**]

 

[**]

[**]

 

[**]

 

 

 

[**]

[**]

 

[**]

 

[**]

 

[**]

 

[**]

 

[**]

[**]

 

[**]

 

[**]

 

[**]

 

 

[**]

 

[**]

 

 

 

 

 

 

 

 

 

 

 

 

 

[**]

 

 

 

 

 

[**]

 

[**]

 

[**]

[**]

 

[**]

 

 

 

[**]

 

 

[**]

 

[**]

 

[**]

 

[**]

 

[**]

[**]

 

[**]

 

 

 

[**]

[**]

 

[**]

 

[**]

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

[**]

 

[**]

 

[**]

[**]

 

[**]

 

 

 

[**]

 

 

[**]

 

[**]

 

[**]

 

[**]

 

[**]

[**]

 

[**]

 

 

 

[**]

[**]

 

[**]

 

[**]

 

[**]

 

[**]

 

[**]

 

 

[**]

 

 

 

[**]

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

[**]

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

[**]

 

[**]

 

[**]

 

[**]

 

[**]

 

[**]

[**]

 

[**]

 

[**]

 

[**]

[**]

 

[**]

 

[**]

 

[**]

 

[**]

 

[**]

[**]

 

[**]

 

[**]

 

[**]

[**]

 

[**]

 

[**]

 

[**]

 

[**]

 

[**]

[**]

 

[**]

 

[**]

 

[**]

 

 

[**]

 

[**]

 

[**]

 

[**]

 

[**]

[**]

 

[**]

 

[**]

 

[**]

[**]

 

[**]

 

[**]

 

 

 

[**]

 

[**]

[**]

 

[**]

 

[**]

 

[**]

 

 

[**]

 

[**]

 

 

 

[**]

 

[**]

[**]

 

[**]

 

[**]

 

[**]

 

ii

--------------------------------------------------------------------------------

 

 

 

[**]

 

[**]

 

 

 

[**]

 

[**]

[**]

 

[**]

 

[**]

 

[**]

 

 

[**]

 

[**]

 

[**]

 

[**]

 

[**]

[**]

 

[**]

 

[**]

 

[**]

 

 

[**]

 

[**]

 

 

 

[**]

 

[**]

[**]

 

[**]

 

[**]

 

[**]

 

 

[**]

 

[**]

 

 

 

[**]

 

[**]

[**]

 

[**]

 

[**]

 

[**]

 

 

[**]

 

[**]

 

 

 

[**]

 

[**]

[**]

 

[**]

 

[**]

 

[**]

 

 

[**]

 

[**]

 

 

 

[**]

 

[**]

[**]

 

[**]

 

[**]

 

[**]

 

 

[**]

 

[**]

 

 

 

[**]

 

[**]

[**]

 

[**]

 

[**]

 

[**]

[**]

 

[**]

 

[**]

 

 

 

[**]

 

[**]

[**]

 

[**]

 

[**]

 

[**]

 

 

[**]

 

[**]

 

 

 

[**]

 

[**]

[**]

 

[**]

 

[**]

 

[**]

 

 

[**]

 

[**]

 

 

 

[**]

 

[**]

[**]

 

[**]

 

[**]

 

[**]

 

 

[**]

 

[**]

 

 

 

[**]

 

[**]

[**]

 

[**]

 

[**]

 

[**]

 

 

[**]

 

[**]

 

 

 

[**]

 

[**]

[**]

 

[**]

 

[**]

 

[**]

 

 

[**]

 

[**]

 

 

 

[**]

 

[**]

[**]

 

[**]

 

[**]

 

[**]

 

 

[**]

 

[**]

 

[**]

 

[**]

 

[**]

[**]

 

[**]

 

[**]

 

[**]

[**]

 

[**]

 

[**]

 

 

 

[**]

 

[**]

[**]

 

[**]

 

[**]

 

[**]

 

 

[**]

 

[**]

 

[**]

 

[**]

 

[**]

[**]

 

[**]

 

[**]

 

[**]

 

 

[**]

 

[**]

 

 

 

[**]

 

[**]

[**]

 

[**]

 

[**]

 

[**]

[**]

 

[**]

 

[**]

 

 

 

[**]

 

[**]

[**]

 

[**]

 

[**]

 

[**]

 

 

[**]

 

[**]

 

 

 

[**]

 

[**]

[**]

 

[**]

 

[**]

 

[**]

 

 

[**]

 

[**]

 

 

 

[**]

 

[**]

[**]

 

[**]

 

[**]

 

[**]

 

 

[**]

 

[**]

 

[**]

 

[**]

 

[**]

[**]

 

[**]

 

[**]

 

[**]

[**]

 

[**]

 

[**]

 

 

 

[**]

 

[**]

[**]

 

[**]

 

[**]

 

[**]

 

 

[**]

 

[**]

 

 

 

[**]

 

[**]

[**]

 

[**]

 

[**]

 

[**]

 

iii

--------------------------------------------------------------------------------

 

SCHEDULE 1.1(c)

 

TRANSFERRED CONTRACTS

 

[**]

 

--------------------------------------------------------------------------------

 

SCHEDULE 1.1(e)

 

TRANSFERRED RECORDS

 

1.                                      A list of the Contact Information
(including email and telephone number) for the principal contacts associated
with such Transferred Contracts, which list shall be delivered to the Purchaser
on the Closing Date.

 

2.                                      The Seller’s Laboratory Notebooks, which
shall be delivered to the Purchaser on the Closing Date.

 

3.                                      The Seller’s results of experiments that
have been scanned and added to an external hard drive, which shall be delivered
to the Purchaser within five (5) business days after the Closing Date.

 

4.                                      The Seller’s electronic documents that
were included in the Seller’s Virtual Data Room that were made available to the
Purchaser shall be added to the Momenta External Storage Devices (as defined
below), which shall be delivered to the Purchaser within five (5) business days
after the later of (i) the Closing Date or (ii) the date Purchaser provides the
Momenta External Storage Devices to Seller.

 

5.                                      All presentations to the Seller’s board
of directors related to the Transferred IP, business and product plans, and
market studies in the 12 months prior to the Closing Date shall be added to the
Momenta External Storage Devices, which shall be delivered to the Purchaser
within ten (10) business days after the later of (i) the Closing Date or
(ii) the date Purchaser provides the Momenta External Storage Devices to Seller.

 

6.                                      Representative examples of presentations
by the Seller to investors or prospective investors related to the Transferred
IP, business and product plans, and market studies in the 12 months prior to the
Closing Date shall be added to the Momenta External Storage Devices, which shall
be delivered to the Purchaser within ten (10) business days after the later of
(i) the Closing Date or (ii) the date Purchaser provides the Momenta External
Storage Devices to Seller.

 

For purposes of this Schedule 1.1(e) to the Agreement, the term “Momenta
External Storage Devices” shall mean an external hard drive (or drives) and/or
network attached storage device(s) of sufficient data storage size to hold all
of the above-mentioned electronic documents referenced in this Schedule
1.1(e) to the Agreement.  Purchaser acknowledges and agrees to the following:

 

1.                                      Purchaser shall furnish and provide to
Seller the Momenta External Storage Devices for the purpose of transferring the
above-mentioned electronic documents included in the Transferred Records (and
such timelines referenced above will begin on the date of such delivery);

 

2.                                      Purchaser, if requested by Seller, shall
provide reasonable information technology assistance and consulting (only during
normal business hours) in connection with the transfer, duplication and storage
of such electronic documents (if requested by Seller, including on-site or
telephonic assistance (only during normal business hours) in such process and
procedures); and

 

3.                                      Purchaser shall arrange for both the
delivery and pickup of such Momenta External Storage Devices once the
above—mentioned electronic documents included in the Transferred Records have
been transferred to such Momenta External Storage Device.

 

--------------------------------------------------------------------------------

 

SCHEDULE 1.6

 

ALLOCATION SCHEDULE

 

Asset

 

Fair Value

 

 

 

 

 

Rockefeller License Agreement

 

$

[**]

 

IP/know-how and scientific notebooks

 

$

[**]

 

Physical Inventory of sialylation enzyme, IVIG, [**] cell lines

 

$

[**]

 

 

 

 

 

Fair Value of Intangible Assets

 

$

[**]

 

 

Note: The contingent consideration (milestones) is not included as part of the
purchase price allocation.

 

--------------------------------------------------------------------------------

 

SCHEDULE 4.4

 

DISPUTE RESOLUTION

 

1.                                      If any Indemnitee has incurred or
suffered or claims to have incurred or suffered, or believes that it may incur
or suffer, Damages for which it is or may be entitled to be held harmless,
indemnified, compensated or reimbursed under Section 4 of the Agreement or for
which it is or may be entitled to a monetary remedy (such as in the case of a
claim based on intentional misrepresentation  or fraud), such Indemnitee may
deliver a notice of claim (a “Notice of Claim”) to the Seller or the Purchaser
(each, an “Indemnitor”).  Each Notice of Claim shall: (a) state that such
Indemnitee believes that such Indemnitee is or may be entitled to
indemnification, compensation or reimbursement under Section 4 of the Agreement
or is or may otherwise be entitled to a monetary remedy; (b) contain a brief
description of the circumstances supporting such Indemnitee’s belief that such
Indemnitee is so entitled to indemnification, compensation or reimbursement or
is or may otherwise be entitled to a monetary remedy; and (c) if practicable,
contain a good faith, non-binding, preliminary estimate of the aggregate dollar
amount of actual and potential Damages that have arisen and may arise as a
result of such circumstances (the aggregate amount of such estimate, as it may
be modified by such Indemnitee in good faith from time to time, being referred
to as the “Claimed Amount”).

 

2.                                      During the 30-day period commencing upon
delivery by an Indemnitee to the Indemnitor of a Notice of Claim (the “Dispute
Period”), the Indemnitor may deliver to the Indemnitee who delivered the Notice
of Claim a written response (the “Response Notice”) in which the Indemnitor:
(a) agrees that the full Claimed Amount is owed to the Indemnitee; (b) agrees
that part, but not all, of the Claimed Amount (the “Agreed Amount”) is owed to
the Indemnitee; or (c) indicates that no part of the Claimed Amount is owed to
the Indemnitee.  If the Response Notice is delivered in accordance with clause
“(b)” or “(c)” of the preceding sentence, the Response Notice shall also contain
a brief description of the facts and circumstances supporting the Indemnitor’s
claim that only a portion or no part of the Claimed Amount is owed to the
Indemnitee, as the case may be. Any part of the Claimed Amount that is not
agreed to be owed to the Indemnitee pursuant to the Response Notice (or the
entire Claimed Amount, if the Indemnitor asserts in the Response Notice that no
part of the Claimed Amount is owed to the Indemnitee) being referred to as the
“Contested Amount” (it being understood that the Contested Amount shall be
modified from time to time to reflect any good faith modifications by the
Indemnitee to the Claimed Amount).  If a Response Notice is not received by the
Indemnitee prior to the expiration of the Dispute Period, then the Indemnitor
shall be conclusively deemed to have agreed that the full Claimed Amount is owed
to the Indemnitee.

 

3.                                      In the case where the Seller is the
Indemnitor, if: (a) the Indemnitor delivers a Response Notice to the Indemnitee
agreeing that the full Claimed Amount is owed to the Indemnitee; or (b) the
Indemnitor does not deliver a Response Notice during the Dispute Period, then,
the Claimed Amount shall be deducted from the Milestone Payments (when and if
such amounts become due and payable pursuant to Section 1.3).

 

4.                                      In the case where the Seller is the
Indemnitor, if the Indemnitor delivers a Response Notice to the Indemnitee
during the Dispute Period agreeing that less than the full Claimed Amount is
owed to the Indemnitee, then, the portion of the Claimed Amount which is not the
Contested Amount shall be deducted from the Milestone Payments (when and if such
amounts become due and payable pursuant to Section 1.3).

 

5.                                      If the Indemnitor delivers a Response
Notice to the Indemnitee during the Dispute Period indicating that there is a
Contested Amount, the Indemnitor and the Indemnitee shall attempt in good faith
to resolve the dispute related to the Contested Amount.  If the Indemnitee and
the Indemnitor resolve such

 

--------------------------------------------------------------------------------

 

dispute, then their resolution of such dispute shall be binding on the
Indemnitor and such Indemnitee and a settlement agreement stipulating the amount
owed to the Indemnitee (the “Stipulated Amount”) shall be signed by the
Indemnitee and the Indemnitor and, in the case where the Seller is the
Indemnitor, the Stipulated Amount shall be deducted from the Milestone Payments
(when and if such amounts become due and payable pursuant to Section 1.3).

 

6.                                      If the Indemnitor and the Indemnitee are
unable to resolve the dispute relating to any Contested Amount during the 30-day
period commencing upon the delivery of the Response Notice to the Indemnitee,
then either the Indemnitee or the Indemnitor may submit the claim described in
the Notice of Claim to the federal or state court in the County of Suffolk in
the Commonwealth of Massachusetts as provided for in Section 6.6 of the
Agreement. The court’s authority shall be confined to deciding:  (a) whether the
Indemnitee is entitled to recover the Contested Amount (or a portion thereof),
and the portion of the Contested Amount the Indemnitee is entitled to recover;
and (b) the non-prevailing party in the Proceeding. The final decision of the
court shall include the dollar amount of the award to the Indemnitee, if any
(the “Award Amount”), shall be furnished to the Indemnitor and the Indemnitee in
writing and shall constitute a conclusive determination of the issue(s) in
question, binding upon the Indemnitor and the Indemnitee (the “Resolved
Amount”).  The non-prevailing party in any such Proceeding shall pay the
reasonable expenses (including reasonable attorneys’ fees) of the prevailing
party, and the fees and expenses associated with the Proceeding.  If an
Indemnitee is found to be the prevailing party in any such Proceeding, the
amount of the reasonable fees and expenses of such Indemnitee payable by the
non-prevailing party pursuant to the immediately preceding sentence shall be
added to the Award Amount. The non-prevailing party shall be determined solely
by the court.  If a Contested Amount is finally resolved, then, within 10 days
after the final resolution of such Contested Amount, the Resolved Amount shall
be deducted from the Milestone Payments (when and if such amounts become due and
payable pursuant to Section 1.3) and the Purchaser shall pay to the Seller the
sum of:  the amount, if any, equal to (a) the  remaining Milestone Payments (due
and payable pursuant to Section 1.3); minus (b) the aggregate amount of the
Claimed Amounts and Contested Amounts associated with all remaining Unresolved
Claims.

 

8.                                      In the case where the Seller is the
Indemnitor, pending resolution of a Contested Amount in accordance with the
foregoing procedures, the Purchaser shall be entitled to temporarily withhold
the amount of such Contested Amount from any Milestone Payments. If within 180
days of the applicable Response Notice such Contested Amount has not been
resolved and the Purchaser has not filed a court claim with respect to such
Contested Amount in accordance with the foregoing paragraph 6 above, then such
Contested Amount shall no longer be deemed a Contested Amount, and the Purchaser
shall pay to the Seller such Contested Amount withheld from any Milestone
Payments (when and if such amounts become due and payable pursuant to
Section 1.3).

 

ii

--------------------------------------------------------------------------------

 

LIST OF SCHEDULES:

Schedule 1.1(a)

 

–

 

Transferred IP

Schedule 1.1(b)

 

–

 

Transferred Tangible Assets

Schedule 1.1(c)

 

–

 

Transferred Contracts

Schedule 1.1(e)

 

–

 

Transferred Records

Schedule 1.6

 

–

 

Allocation Schedule

Schedule 4.4

 

–

 

Dispute Resolution

 

LIST OF EXHIBITS:

Exhibit A

 

–

 

Certain Definitions

Exhibit B

 

–

 

Form of Bill of Sale and Assignment Agreement

Exhibit C

 

–

 

Consent of The Rockefeller University

Exhibit D

 

–

 

Letter Agreement from The Rockefeller University

Exhibit E

 

–

 

Form of Assignment and Assumption Agreement

Exhibit F

 

–

 

Earn-Out

Exhibit G

 

–

 

Form of Press Release

Exhibit H

 

–

 

Consent of [**]

Exhibit I

 

–

 

Form of Waiver and Release

 

--------------------------------------------------------------------------------